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The importance of drug metabolites synthesis: the case-study of cardiotoxic 
anticancer drugs 
 
Abstract 
 
Anticancer drugs are presently guarantying more survivors as a result of more powerful drugs 
or combinations of drugs used in therapy. Thus, it has become more crucial to study and overcome the 
side effects of these therapies. Cardiotoxicity is one of the most relevant side effect on the long-term 
cancer survivors, because of its high social and economic impact. Drug metabolism can result in active 
metabolites or toxic metabolites that can lead to important side effects. The metabolites of anticancer 
drugs are possible culprits of cardiotoxicity; however, the cardiotoxicity of many of the metabolites in 
several drug classes was not yet suitably studied so far. On the other hand, the use of prodrugs that are 
bioactivated through metabolism can be a good alternative to obtain more cardio safe drugs. In this 
review, the methods to obtain and study metabolites are summarized and their application to the study 
of a group of anticancer drugs with acknowledged cardiotoxicity is highlighted. In this group of drugs, 
doxorubicin (DOX, 1), mitoxantrone (MTX, 2), cyclophosphamide (CTX, 3), and 5-fluorouracil (5-
FU, 4) are included, as well as the tyrosine kinase inhibitors, such as imatinib (5), sunitinib (6), and 
sorafenib (7). Only with the synthesis and purification of considerable amounts of the metabolites can 
reliable studies be performed, either in vitro or in vivo that allow accurate conclusions regarding the 
cardiotoxicity of anticancer drug metabolites and then pharmacological prevention or treatment of the 
cardiac side effects can be done.  
 
Keywords: Anticancer drugs; Cardiotoxicity; In vitro models; Metabolites; Metabolites synthesis. 
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List of Abbreviations: 
 
ALDH – Aldehyde dehydrogenase  
CAP – Capecitabine 
CML – Chronic myelogenous leukaemia 
CTX – Cyclophosphamide 
CYP – Cytochrome 
Cyd deaminase – Cytidine deaminase 
DPD – Dihydropyrimidine dehydrogenase 
dThdPhase – Thymidine phosphorylase 
DOX – Doxorubicin 
DOXol - Doxorubicinol  
5-dFCyd – 5-deoxy-5-fluorocytidine 
5-dFUrd – 5-deoxy-5-fluorouridine 
FBAL – α-Fluoro-β-alanine 
FLT3 – Fams-like tyrosine kinase-3 
FDA – Food and Drug Administration 
FUPA – α-Fluoro-β-ureidopropionic acid 
5-FU – 5-Fluoruracil 
5-FdUMP – Fluorodeoxyuridine monophosphate 
5-FUTP – Fluouridine triphosphate 
5-FdUTP – Fluorodeoxyuridine triphosphate 
5-FUMP – 5’-Fluorouridine-5’-monophosphate 
5-FUDP – 5-Fluorouridine-5’-diphosphate 
5-FdUDP – 5-Fluoro-2’-deoxyuridine-5’-diphosphate 
5-FUH2 – 5,6-Dihydro-5-fluorouracil 
GST – Glutathione S-transferase 
h – hours 
JNK – Jun N-terminal kinase  
MTX – Mitoxantrone 
NADPH - Nicotinamide adenine dinucleotide phosphate 
NAT – N-acetyl transferase 
PDGFR – Platelet-derived growth factor receptors 
RARG – Retinoic acid receptor gamma 
ST – Sulphotransferases 
TKIs – Tyrosine kinase inhibitors 
TOP - Topoisomerase 
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VEGFRs – Vascular endothelial growth factor receptors 
 
 
Introduction 
 
During the drug development process, a selected drug candidate is thoroughly 
evaluated regarding the information of its metabolic pathway and pharmacokinetics. This 
information is required by regulatory agencies to better assess the safety of a drug candidate 
before it can be approved (Lin and Lu, 1997). Over time in the drug development process, 
many regulatory guidelines have chosen to incorporate metabolites on their safety evaluation 
guidelines (Baillie et al., 2002) mainly because of putative active/toxic metabolites formation. 
In fact, many drugs can give rise to one or more metabolites with biological activity (Lin and 
Lu, 1997). It should be noted that to the pharmaceutical researchers and regulatory agencies, 
the patient’s safety is of paramount concern, especially if metabolites are suspected to be 
reactive and toxic (Luffer-Atlas, 2008). 
Concerning toxicity, the early information on human metabolism of a new drug is 
essential to foresee the potential clinical drug-drug interactions and to select the appropriate 
animal species where those drugs are to be tested in pre-clinical studies. Regulatory agencies 
require human risk assessment to show that the systemic exposure of an unchanged drug and 
its major metabolites do not exceed the safety margin. Ideally, the metabolite profile of a drug 
obtained in vitro should generally mimic the in vivo metabolite pattern; however, in vitro 
models have limitations. Therefore, the comparison between animal and human metabolism 
should be performed in the early stage of the drug development process (Lin and Lu, 1997).  
Different enzymes catalyse different steps of the metabolic pathways and these 
enzymes catalyse the biotransformation of xenobiotics, including drugs used in the clinical 
practice. Drug metabolism is usually divided in two phases: phase I or functionalization 
reactions and phase II or conjugation reactions. Phase I metabolism includes oxidation, 
reduction, hydrolysis, and hydration reactions. The cytochrome (CYP) P450 system has a 
major role in the phase I reactions. The functionalization step usually transforms a drug into a 
more soluble and easier to eliminate drug. The phase II reactions or conjugation reactions 
include glucuronidation, sulfation, amino acid conjugation, acetylation, methylation, or 
glutathione conjugation and they usually facilitate elimination (Gibson and Skett, 2001). 
As stated, the drug metabolism/biotransformation can lead to pharmacological 
activation or inactivation (Scheme 1). When metabolism results in the pharmacological 
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activation with formation of pharmacologically active metabolites, a process of bioactivation 
occurs. Fura et al. defined an active metabolite, as "a pharmacologically active metabolic 
product with activity against the same pharmacological target as the parent molecule". This 
concept of active metabolite differs from the definition of reactive metabolites that correspond 
to chemically reactive intermediates formed during metabolism. These reactive 
intermediaries, when bound to biomolecules via covalent bonds, may elicit toxicity. 
Parameters, such as the contribution to the total pharmacological activity of a given dose of 
the parent compound, its intrinsic activity, and the relative concentration at the action site, 
measure the importance of a particular active metabolite (Fura et al., 2004). Regarding the 
pharmacokinetic data, the mechanisms of distribution and clearance of active metabolites are 
often differ from the parent drug. Therefore, to predict the therapeutic outcome and explain 
the toxicity of specific drugs, it is important to understand the kinetics of the formation of an 
active metabolite (Lin and Lu, 1997).  
Metabolites can be synthesized and tested in appropriate models if they are suspected 
to elicit a pharmacological or toxicological effect. Some novel drugs have been discovered 
during metabolite characterization of drug candidates, namely in the case of paliperidone, the 
active metabolite of the antipsychotic risperidone, and desvenlafaxine, the active metabolite 
of the antidepressant venlafaxine, among others (Obach, 2013). In fact, some of these new 
compounds may be better drug candidates in terms of safety and effectiveness than their 
parent compounds since they may have characteristics such as better extent of delivery, 
disposition kinetics, clearance, lower interindividual variability, and/or less potential for 
accumulation (Liu and Jia, 2007, Obach, 2013). 
Another biotransformation process important in the drug discovery process is 
associated with the prodrug design. A prodrug can be defined as a pharmacologically inactive 
drug that turns into a pharmacologically active form, after in vivo administration. This 
transformation can occur either by metabolism or by spontaneous chemical breakdown 
(Rautio et al., 2008). Targeted prodrug approach is one of the new trends in the treatment of 
cancer. An ideal prodrug is a drug that increases the bioavailability, eliminates undesirable 
side effects and enhances the half-life of drugs. Prodrugs of anticancer agents are usually 
designed to be organ-specific and tumour-specific targeting. An alternative strategy used to 
achieve the activation site is the use of enzyme immunoconjugates towards antigens 
expressed on tumours cells and therefore the drug can target the tumour site more precisely 
(Rooseboom et al., 2004). 
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 The aim of this review is to highlight the importance of the metabolites of various 
anticancer drugs including conventional chemotherapy agents such as doxorubicin (DOX, 1), 
mitoxantrone (MTX, 2), cyclophosphamide (CTX, 3), 5-fluorouracil (5-FU, 4), imatinib (5), 
sunitinib (6) and sorafenib (7), since they can be directly involved in the cardiotoxicity of 
these anticancer drugs (Figure 1). In vitro and in vivo studies are performed to discover the 
metabolite pattern of a given drug. However, the use of conventional in vitro and in vivo 
studies may not be sufficient to fully explore all compounds for a full chemical and biological 
characterization of the metabolic profile of a given drug, so one has to resort to other 
methods. Those methods may include classical semi-synthesis, total synthesis or biomimetic 
approaches with metabolic enzymes. Herein, studies related with the biological 
characterization and the syntheses of anticancer metabolites (1-7) are detailed. To improve 
their pharmacokinetic and pharmacodynamic features, other derivatives such as prodrugs have 
been studied; therefore, this information is also gathered in this case-study to highlight the 
potential benefits of the prodrug design of anticancer drugs. 
 
Scheme 1 
Figure 1 
 
In vitro and in vivo methods to study metabolism 
 
In vitro and animal in vivo studies are performed in the pre-clinical stage to assess the 
toxicity of a drug and the metabolite profile before the drug goes into human clinical trials. 
This thorough evaluation is done in order to avoid failures and serious toxicity later on in the 
drug development process (Gunaratna, 2000). Early in vivo investigations should assess the 
main metabolic routes (Industry, 2006) and the pharmacokinetic parameters of the most 
prominent compounds selected from in vitro studies (Gunaratna, 2000).  
In vitro studies are suited to determine the potential drug-drug interactions in clinical 
trials. Food and Drug Administration (FDA) guidelines suggest first the use of in vitro studies 
to assess the effect of the drug on the metabolic pathways. If the results indicate possible 
drug-drug interactions, in vivo assays will follow. The main goal of the pre-clinical studies is 
to predict the in vivo outcome in humans. However, despite of the improvement of  in vitro 
assays, the general consensus is that in vitro models are too simplistic to completely replace in 
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vivo studies (Gunaratna, 2000). We can usually assume that potential clinical risks of the 
parent drug and its metabolites have been adequately investigated during nonclinical studies 
when the metabolite profiling of a parent drug is similar qualitatively and quantitatively 
across species, based on the data obtained from in vitro and in vivo metabolism studies (Liu 
and Jia, 2007).  
The in vitro studies during pre-clinical screening are often low-throughput systems. It 
is now possible to better predict the potential drug-drug interactions before clinical trials since 
there is a greater availability of human tissues and recombinant enzymes. In vitro metabolic 
studies have two major goals: identifying the major metabolic pathways of the drug and its 
metabolites, and exploring the effect of the test drug on the metabolism of other drugs. In 
addition, these studies may help to determine that a particular drug is not a substrate for 
certain metabolic pathways. The data obtained allows reducing or even eliminates the need to 
study the possible inhibitory effects of that drug on other drugs metabolized by that particular 
pathway. The first in vitro metabolic system used to study drug metabolism involves hepatic 
enzymes or tissue preparations (Gunaratna, 2000) because liver is the main organ responsible 
for the biotransformation of xenobiotics. Even so, other organs are also involved in drug 
biotransformation (Asha and Vidyavathi, 2010), but they will not be reported here for 
systematic purposes. The metabolites formed in the liver can, through blood distribution, 
reach most of the organs, namely the heart, where they can exert their effects. In vitro studies 
can give information about the metabolite’s stability, profile and identification; they will 
allow interspecies comparisons, toxicology species selection, CYP induction/inhibition and 
drug/drug interaction studies, CYP isoform identifications and phase II enzyme studies 
(Gunaratna, 2000). Several in vitro human liver models have been developed, including: 
supersomes, cytosol, cell lines, transgenic cell lines, microsomes, isolated hepatocytes, tissue 
slices, S9 fractions, and isolated perfused liver (Table 1). All of these models, with the 
exception of primary hepatocytes, cell lines, liver slices, and isolated perfused liver require 
exogenous cofactors to attain the maximum enzymatic activity (Asha and Vidyavathi, 2010). 
The following table 1 summarizes most of the in vitro models used in metabolism studies. 
 
Table 1 
As stated, as part of the drug development process, pharmaceutical companies are 
required by regulatory agencies to study the metabolism of a given drug candidate. It is a part 
of the preclinical absorption-distribution-metabolism-excretion-toxicity (ADMET) studies, 
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which are usually performed in vivo using animal models like rat, mice, dog, and monkey  
(Industry, 2006). The pharmacokinetic evaluation after multiple dosing can also be evaluated 
to identify potential auto induction. Moreover, even when two drugs share a common 
metabolic pathway, it may not lead to clinically significant pharmacokinetic interactions when 
co-administered to a patient. Whether the two co-administered drugs will interact in humans 
will depend on various factors, including the relative affinities of each drug for the binding 
site on the metabolizing enzyme as well as the effective free drug concentration available 
locally for binding. However, a small pharmacokinetic interaction can result in significant 
pharmacodynamic adverse effects, especially for drugs with narrow therapeutic index 
(Bjornsson et al., 2003). 
In vivo drug metabolism studies to assess distribution and disposition of major 
metabolites and the human unique metabolites are usually done by evaluating the metabolite 
profiling in blood, selected tissues, urine, and bile. In many cases, metabolites can be easily 
found in other biological matrices than blood, such as excreta (Liu and Jia, 2007). FDA 
guidance defines major metabolites as those identified in human plasma that account for more 
than 10% of the drug related material (administered dose or systemic exposure, whichever is 
lower) (Industry, 2005).  
The evaluation of urine, faeces, and expired air (if the drug and its metabolites are 
expected to be exhaled) from treated animals should use appropriate qualitative and 
quantitative methods. In metabolites detected in animals as well as in humans, adequacy of 
systemic exposure should be assessed by the evaluation of area under the curve (AUC), in 
plasma or serum. The AUC includes both the plasma concentration of the drug candidate and 
the residence time in vivo (Liu and Jia, 2007). 
Pharmacovigilance studies in the later phase of the clinical drug development are 
valuable as a complement to test efficacy/safety. For some drugs, differences in drug safety 
and efficacy may be caused by genetic polymorphisms in drug metabolizing enzymes, drug 
transporters, or drug receptors. It is known that five CYP P450 enzymes - CYP1A2, 2C9, 
2C19, 2D6, and 3A4 - are responsible for metabolizing most commercially available drugs. 
The CYP3A4 enzyme accounts for the biotransformation of 50% of these drugs. CYP2C9, 
CYP2C19, and CYP2D6 enzymes account for approximately another 40% of drug 
metabolism by CYP P450s and they exhibit high levels of genetic polymorphism (Bjornsson 
et al., 2003). Cyclophosphamide (CTX, 3) is the anticancer drug addressed in this review that 
has the greater bulk of data regarding genetic polymorphisms of metabolic enzymes. CTX (3)  
is a prodrug, thus to exert its antitumour activity, it requires to be metabolic activated by 
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hepatic CYP P450 enzymes to form the active alkylating species (Moore, 1991). Moreover, 
CTX (3) is also metabolized by glutathione S-transferase (GST) and aldehyde dehydrogenase 
(ALDH) enzymes. Several studies have been performed to determine if genetic 
polymorphisms of these enzymes may affect the pharmacokinetics of CTX (3) and thereby its 
toxicity and therapeutic efficacy (Yule et al., 2004, Petros et al., 2005, Ekhart et al., 2008, 
Jamieson et al., 2014, Veal et al., 2016). The polymorphisms on CYP isoenzymes have 
extensively researched, mainly CYP2B6, CYP2C19, and CYP3A4. However, contradictory 
results have been published; some authors state that those polymorphisms can impact the 
therapy response rate and cancer recurrence (Yule et al., 2004, Petros et al., 2005, Nakajima 
et al., 2007), while other studies (Ekhart et al., 2008, Jamieson et al., 2014, Veal et al., 2016) 
observed that pharmacogenetic factors had only a minor or no influence in the treatment 
response and in future cancer recurrence.  
The polymorphism of the metabolic enzymes involved in 5-FU (4) catabolism is also relevant 
to its effects. Eighty-five percent to 90% of the intravenous administered 5-FU (4) is rapidly 
catabolized by hepatic dihydropyrimidine dehydrogenase (DPD). DPD is the initial and rate-
limiting enzyme in the pathway that catabolizes the pyrimidines and its polymorphism is 
related with 5-FU (4) adverse effects or clinical response. There is a strong association 
between DPD gene polymorphism that leads to a partial DPD activity deficiency and 
fluoropyrimidine-related toxicity in cancer patients (Gross et al., 2008). Concerning DOX (1) 
or MTX (2), the polymorphisms of the efflux transporter proteins are more broadly researched 
and scarce data exist regarding the enzymes involved in their metabolism. Aldo-
ketoreductases are involved in the metabolism of DOX (1) and some genotypes were 
associated with higher haematological toxicity, longer progression-free survival and overall 
survival after DOX (1)-based therapy (Voon et al., 2013). Regarding the targeted therapy 
drugs mentioned herein, the existing data is occasional and new studies need to be perform to 
better elucidate the influence of genetic polymorphisms of the metabolic enzymes on their 
toxic effects and also on their clinical efficacy. Data on imatinib (5) generally rules out 
biotransformation as having a relevant interest to the interindividual variability of drug 
efficacy, resistance or toxicity (Rochat, 2005, Gardner et al., 2006, Seong et al., 2013). 
Nevertheless, information on imatinib (5), shows that polymorphism of CYP3A5*3 was been 
associated with lower resistance to treatment in Malaysian chronic myeloid leukaemia 
patients (Maddin et al., 2016). Studies on sorafenib (7) show that polymorphisms on uridine 
glucuronosyl transferases (UGT), namely of UGT1A1 and UGT1A9, lead to abnormally high 
area under the curve in treated-patients (Peer et al., 2012).   
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Although the liver is the most important drug metabolizing organ, the gut is also very 
important in the biotransformation of the drugs. Moreover, for orally administered drugs, the 
enzymes in the gut wall provide an important and highly sensitive site for drug interactions 
and drug biotransformation. The main intestinal biotransformation enzymes responsible for 
phase I reactions include CYP, esterases, epoxide hydrolase and alcohol dehydrogenase, and 
for phase II reactions glucosyltransferases, sulfotransferases (ST), N-acetyl-transferases 
(NAT), and GST (Liu and Jia, 2007). 
 
 
Anticancer drugs and metabolites 
 
Chemotherapy-induced cardiotoxicity is a major limitation to the effective use of 
several anticancer drugs. These include both conventional chemotherapy and targeted therapy 
agents, with anthracyclines being the most extensively studied group. Anthracyclines and 
their metabolites cause a progressive heart failure and, consequently can result in cardiac 
death (Maharsy, 2015). The next section describes cytotoxic drugs used to treat cancer, DOX 
(1), MTX (2), CTX (3), and 5-FU (4) and their metabolites, since in the published data those 
metabolites may have an important role in the induced-cardiotoxicity of these drugs.  
 
 
Conventional cytotoxic drugs 
  
The chemotherapeutic agents used to treat cancer in children and adults can cause a 
wide spectrum of short- and long-term cardiotoxic effects. Those effects can result, at the 
worst case scenario on cardiac transplantation or death (Raj et al., 2014). In particular, 
anthracyclines like DOX (1), the most widely prescribed chemotherapeutic in children, 
(Smith et al., 2010, Lipshultz et al., 2013) MTX (2), CTX (3), 5-FU (4), and taxanes show 
superior antitumour activity in many solid or hematologic malignancies (Menna et al., 2012). 
However, anthracyclines induce off-target cardiotoxicity that may progress to dilated 
cardiomyopathy and systolic heart failure (Lipshultz et al., 2013, Salvatorelli et al., 2015). 
The cardiomyopathy risk is anthracycline cumulative dose-dependent. Cumulative dose of 
400–450 mg of DOX/m2 or superior can be cause a direct cardiotoxic insult that eventually 
can progress toward symptomatic cardiac events (Menna et al., 2012). Even so, cardiotoxicity 
has been detected in lower life time cumulative doses (Menna et al., 2012, Raj et al., 2014). 
JU
ST
 AC
CE
PT
ED
DOX (1) is able of DNA intercalation and topoisomerase 2 (Top2) inhibition. As a result, 
RNA and DNA polymerases activity is impaired and, consequently, they cause DNA strand 
scission and interfere with cell replication leading to cell death (Raj et al., 2014).  
Anthracyclines-induced cardiomyopathy by generation of excess reactive oxygen 
species (ROS) is the most widely accepted hypothesis to explain their cardiotoxicity. ROS are 
formed by electron exchange between the anthracycline quinone moiety and oxygen 
molecules and other cellular electron donors. In addition, anthracyclines can also generate 
ROS through the formation of complexes with iron and then undergo redox cycling (Menna et 
al., 2012, Raj et al., 2014, Vejpongsa and Yeh, 2014). In fact, the classical notion regarding 
DOX (1)-induced cardiotoxicity is that its redox cycling with quinone formation and cardiac 
oxidative stress (Costa et al., 2013, Sawyer 2013) promotion are responsible for its 
cardiotoxicity. Recently, it was found that human induced pluripotent stem cell–derived 
cardiomyocytes (hiPSC-CMs) of patients that showed DOX (1)-induced cardiotoxicity had 
substantially lower levels of basal metabolism and mitochondrial content, along with 
decreased cell viability, impaired calcium handling, decreased antioxidant activity, and 
increased ROS production. Therefore, those cells are possible biomarkers to the future 
cardiotoxicity induced by DOX (1) (Burridge et al., 2016). Moreover, exciting new facts 
regarding DOX (1)-induced cardiotoxicity have been recently published (Zhang et al., 2012, 
Aminkeng et al., 2015). There are two cellular Top2 enzymes: Top2α and Top2β, and DOX 
(1) inhibits both. Top2α is overexpressed in tumour cells while adult mammalian 
cardiomyocytes express Top2β. Zhang et al. (2012) showed that cardiomyocyte-specific 
deletion of Top2β protects mice of DOX (1)-induced progressive heart failure. The authors 
suggested that DOX (1) inhibition of Top2β activity impairs mitochondrial biogenesis and 
leads to oxidative stress. Moreover, a genetic variant of Retinoic Acid Receptor Gamma 
(RARG) has been associated in humans with increased cardiotoxicity after anthracycline 
regiments in children subjected to anthracycline treatments. RARG was found to repress 
Top2b expression (Aminkeng et al., 2015), thus further corroborating Top2β involvement in 
the cardiotoxicity promoted by anthracyclines.   JU
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Doxorubicin (DOX) 
 
DOX (1) (former generic name, adriamycin), the most commonly used anthracycline, 
has been used since the late 1960s to treat solid and hematologic malignancies. DOX (1) is 
used in the treatment of breast cancer, lymphomas, myelogenous or lymphoblastic acute 
leukaemia’s, and osteosarcoma (Maharsy, 2015). DOX (1) displays extensive tissue uptake, 
high volume of distribution, and reasonable plasma protein binding; it is administered 
intravenously and it is highly metabolized, and is excreted via bile (50%) and urine (5-12%). 
In bile, about 30% is excreted in form of conjugates, although their structures were not yet 
elucidated (Crombag et al., 2016). 
Doxorubicinol (DOXol, 8) (Scheme 2) is formed from DOX (1) by a two-electron 
reduction of the side chain at C-13 carbonyl group of DOX (1) by nicotinamide adenine 
dinucleotide phosphate (NADPH)-dependent cytoplasmic aldo/ketoses or carbonyl reductases 
(Menna et al., 2012, Reis-Mendes et al., 2016b). DOXol (8), an alcohol metabolite of DOX 
(1), has been implicated in the cardiotoxicity observed in DOX (1)-treated patients, largely 
due to the inhibition of Na
+
/K
+
 channels present in the cardiac sarcolemma. DOXol (8) also 
inhibits the calcium pump of the heart and skeletal muscle and the proton pump of cardiac 
mitochondria (Boucek Jr et al., 1987, Olson et al., 1988).  DOXol (8) is less effective in 
killing cancer cells but it is more potent than its parent compound in impairing the myocardial 
cell (Menna et al., 2012, Reis-Mendes et al., 2016b). When DOX (1) is administered, the 
concentration of DOXol (8) gradually prevails over that of DOX (1) concentration over time, 
making DOXol (8) the most toxic species at the time when late stage cardiomyopathy is 
developed (Menna et al., 2012). Inhibition of the aldo/keto reductases that catalyse the 
reduction results in more DOX (1) to kill cancer cells and less DOXol (8) to compromise 
cardiac function (Olson et al., 1988); however, cardiotoxicity still persists when DOXol (8) 
formation is compromised.  
Other metabolites can be formed after DOX administration (Scheme 2) like 7-
hydroxydoxorubicin aglycone (9) by a hydrolytic cleavage and 7-deoxydoxorubicinol 
aglycone (10) and 7-deoxydoxorubicin aglycone (11) by a reductive cleavage of the 
glycosidic ring at C-7. Aglycones may be demethylated and conjugated via the sulfate or the 
glucuronide pathways. Sulfonated (demethyldeoxydoxorubicinol aglycone 4-O-sulfate, 12) 
and glucuronidated (demethyldeoxydoxorubicinol aglycone 4-O-β-glucuronide, 13) 
metabolites have been identiﬁed as urinary metabolites, but this biotransformation route 
seems to be limited to humans (Takanashi and Bachur, 1976, Reis-Mendes et al., 2016b).  
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 Scheme 2 
 
A study showed that the aglycones 9, 11, and 14 can be reliably detected and can also 
significantly contribute to the (cardiac) toxicity of DOX (1) (Joerger et al., 2005). In fact, 
aglycones are shown to be powerful mitochondrial toxins therefore largely affecting the heart 
(Reis-Mendes et al., 2016b). 
 
 
In vitro models to study the metabolism of doxorubicin. Several in vitro models can be used to 
characterize DOX (1) metabolism. DOX (1) was converted into the corresponding alcohol, 
DOXol (8), after incubation of the supernatant of rat liver homogenate with DOX (1). Also, 
the reductive glycosidic cleavage was quite significant when rat liver microsomes were 
incubated with DOX (1) resulting in the formation of 7-deoxydoxorubicinol aglycone (10) 
and 7-deoxydoxorubicin aglycone (11) (Weenen et al., 1984). 
In a study of 2011, Sharka and colleagues studied the metabolism of anthracyclines in 
human liver microsomes and demonstrated that for concentrations above 100 µM, the 
reduction of DOX (1) to DOXol (8) is not the major metabolic pathway. This is due to the 
high activity of microsomal hydrolases that leads to increased concentrations of 7-
hydroxydoxorubicin aglycone (9) and its reduced metabolite 7-hydroxydoxorubicinol 
aglycone (14). The microsomal fraction was also responsible for the reduction of the 
hydrolysed DOX (1) to its 7-deoxydoxorubicin aglycone (11) (Skarka et al., 2011). These 
reactions may contribute to the resistance of tumour cells against DOX (1) treatment since 
these metabolites possess a lower cytotoxic ability (Licata et al., 2000). 
The metabolism in human cytosol fractions, with high levels of cardiac carbonyl 
reductases, generates substantial amounts of 7-deoxydoxorubicin aglycone (11) (a product 
reflecting the reductive cleavage of the glycosidic bond). Moreover, when increasing the 
concentration of cytosolic proteins the yield of this metabolite also increases. This increase 
was not accompanied by the formation of the corresponding alcohol metabolite, 7-
deoxydoxorubicinol aglycone (10), thus suggesting that 7-deoxydoxorubicin aglycone (11) 
was not a good substrate for cardiac carbonyl reductases. In human cardiac cytosol fractions, 
DOX (1) is converted to the secondary alcohol metabolite (DOXol, 8) and to a broad panel of 
7-hydroxy- or 7-deoxyaglycones: 7-deoxydoxorubicin aglycone (11), 7-hydroxydoxorubicin 
aglycone (9), and 7-hydroxydoxorubicinol aglycone (14). These metabolites have the 
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chemical prerequisites to cause cardiotoxicity and the cardiotoxic potential of these 
metabolites is influenced by changes in the properties of the anthracycline molecule: 
deglycosidation decreases the polarity of the anthracycline allowing their faster displacement 
across in biological membranes. Also, the conversion of DOX (1) to DOXol (8) makes the 
anthracycline molecule slightly more polar, which favours its retention inside the 
cardiomyocytes (Licata et al., 2000). 
Minotti et al. performed experiments in cytosolic fractions of human myocardium 
obtained during bypass surgery (Minotti et al., 1995, Minotti et al., 2000). This model 
provides an ethically acceptable system for predicting the formation metabolites in the human 
heart (Minotti et al., 2000) and avoids potential pitfalls, since studies in laboratory animals 
are heavily influenced by species related differences in drug metabolism (Licata et al., 2000). 
The formation of DOXol (8) was obtained in iron-depleted cytosolic fractions of human 
myocardium enriched with NADPH and incubated with DOX (1). It was also demonstrated 
that 7-hydroxydoxorubicin aglycone (9) is not a good substrate for carbonyl reduction 
(Minotti et al., 2000).  
 
 
Mitoxantrone (MTX) 
 
MTX (2) is a synthetic anthraquinone that belongs to the synthetic anthracenediones 
family (Ehninger et al., 1990). It is an antineoplastic agent with antiviral, antibacterial, and 
antitumour properties with a large spectrum of antitumour activity. MTX (2) is used to treat 
breast cancer, acute leukaemia’s, acute lymphomas, and multiple sclerosis in adults (Costa et 
al., 2013). At a chemical level, the main alteration of MTX (2) when compared to 
anthracyclines is the replacement of the amino sugar on the anthracyclines for an 
aminoalkylalcohol chain (Pratt et al., 1986). This compound was structurally designed to have 
little or no cardiotoxicity.  Batra et al., confirmed the lower short and long term MTX (2) 
toxicity when compared to DOX (1) (Batra et al., 1986) in animal models; however, the 
clinical practice and other animal studies did not corroborate the data first gathered (Pratt et 
al., 1986, Rossato et al., 2014, Dores-Sousa et al., 2015).  
MTX (2) has low absorption when administered orally and for this reason MTX (2) is 
administered via intramuscular or by intraperitoneal injection (Batra et al., 1986). The main 
MTX (2) metabolites (Scheme 3) were identified as the monocarboxylic acid (16) and 
dicarboxylic acid (17) resulting from the oxidation of the terminal hydroxyl groups of the side 
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chains. These two metabolites are more polar than MTX (2) (Chiccarelli et al., 1986, Blanz et 
al., 1991). There are studies confirming that the glucuronide (18) is also an urinary metabolite 
of MTX (2) in humans (Batra et al., 1986), whereas the MTX glutathione (19) metabolite was 
only detected in in vitro models (Scheme 3) so far (Mewes et al., 1993, Rossato et al., 2013).  
 
Scheme 3  
  
 
In vitro models to study the metabolism of mitoxantrone. The metabolic profile of MTX (2) 
has been studied by using various methods, such as primary cultures of hepatocytes isolated 
from rats, rabbits, and humans (Richard et al., 1991), microsomes and hepatic S9 fractions 
(Rossato et al., 2013).   
In a study with isolated perfused rat liver model, it was demonstrated that MTX (2) 
was extensively and rapidly metabolized and the mono- (16) and dicarboxylic (17) acid 
derivatives represented a very low percentage of the metabolites excreted in bile (Ehninger et 
al., 1984). 
In another study, Wolf et al., identified the glutathione (19)- and glucurono (18)-
conjugates of MTX (2) as the main MTX (2) metabolites in rat liver microsomal fractions and 
in hepatocyte homogenates (Wolf et al., 1986). In the case of the cyclic naphtoquinoxaline 
(20) metabolite, it has been stated that it has anticancer properties (Panousis et al., 1997) but 
it seems a more cardiosafe metabolite (Shipp et al., 1993, Reis-Mendes et al., 2016a) when 
compared with MTX (2), at least in in vitro models, namely neonatal cardiomyocytes of 
cyclic naphtoquinoxaline (20) and in H9c2 differentiated cells. Moreover, the other 
metabolites were not yet studied regarding their cardiotoxicity at this point.  
In a recent study, Rossato et al. studied the metabolic profile of MTX (2) using 
phenobarbital-induced hepatic S9 fraction from adult rats and five metabolites were 
identified. Those metabolites were the naphtoquinoxaline metabolite (20), acetoxy ester 
metabolite (21), glutathione metabolites (22, 23) and the monocarboxylic acid derivative (24) 
(Scheme 3) (Rossato et al., 2013). The metabolites 22 and 23 were previously found after 
incubation of MTX (2) with horseradish peroxidase and glutathione (Blanz et al., 1991). 
Cyclic naphthoquinoxaline 20, a product of biotransformation of MTX (2) in vivo in humans, 
pigs, and rats (Blanz et al., 1991, Rossato et al., 2013), is a product of metabolism of CYP 
P450 enzymes or peroxidases (Reis-Mendes et al., 2016b). The presence of metabolite cyclic 
naphthoquinoxaline 20 in the urine of different species proves for the first time the existence 
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of intracellular enzymes capable of oxidizing mitoxantrone in vivo (Blanz et al., 1991) 
Moreover, Rossato et al, evaluated the metabolic profile in vivo in rats that received 7.5 
mg/kg of MTX (2) 24-h before. In the liver of the MTX-treated animals were identified 4 
metabolites: cyclic naphtoquinoxaline (20), acetoxy ester metabolite (21), glutathione 
metabolite (22), and monocarboxylic acid derivative of MTX (24), whereas, in the heart the 
cyclic naphtoquinoxaline (20) was the only metabolite detected (Rossato et al., 2013). 
In another study that aimed to explore the biotransformation of MTX (2), MTX (2) 
was incubated with rat, rabbit, and human hepatocytes. When MTX (2) was incubated with 
rat hepatocytes, it was rapidly taken up by the cells as observed by the distribution of the blue 
drug within the cells. Two metabolites were produced in rabbit and human hepatocytes but 
not in rat hepatocytes, the mono- (16) and dicarboxylic (17) acids. Moreover, the glutathione 
(22), cysteinylglycine (25), cysteine derivatives of MTX (26), and a thioether conjugate of 
MTX (27) (Scheme 3) were also identified (Mewes et al., 1993). In the same study, human 
HepG2 hepatoma cells were incubated with MTX (2) for 24 h and in the cell lysates of 
HepG2 cells, 2-(L-cysteine-5-yl)-MTX (26) was identified, while the glutathione metabolite 
(22) and cysteinylglycine (25) were not detected. Moreover, the cytotoxic effect of MTX (2) 
on rat hepatocytes revealed that these cells were less sensitive to parental compound and its 
metabolites: only at concentrations above 200 µM a significant cytotoxic effect was observed, 
leading to about 20% cell death, during a 9-h incubation period, while in rat hepatocytes 400 
µM of MTX (2) killed approximately 50% of the hepatocytes. An increasing number of 
hepatocytes were affected after 9 h of incubation, and 20% of hepatocytes were killed at 25 
µM according to the leakage of LDH (Mewes et al., 1993).  
 
 
Cyclophosphamide (CTX) 
 
CTX (3) is an alkylating agent widely used as an antitumour agent in the clinical 
practice  (Balis et al., 1983). CTX (3) is commonly used against several types of cancers like 
malignant lymphomas, leukaemia’s, neuroblastoma, retinoblastoma, and carcinomas of the 
ovary, breast, endometrium, and lung, usually in combination with other chemotherapeutic 
agents (De Jonge et al., 2005). CTX (3) is a prodrug extensively metabolised to several 
active/toxic metabolites [4-hydroxycyclophosphamide (28), aldophosphamide (29), 
phosphoramide mustard (30), and acrolein (31)] and inactive/nontoxic metabolites [4-
ketocyclophosphamide (32), carboxyphosphamide (33), dechloroethylcyclophosphamide (34), 
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4-glutathionylcyclophosphamide (35), and diglutathionylphosphoramide mustard (36)] 
(Scheme 4), requiring enzymatic bioactivation to manifest its antitumour activity (De Jonge et 
al., 2005, Reis-Mendes et al., 2016b). The formation of the three inactive/nontoxic 
metabolites corresponds to the detoxification route of CTX (3). The main detoxification 
pathway leads to the formation of carboxyphosphamide (33) from aldophosphamide (29) (De 
Jonge et al., 2005). 4-Hydroxycyclophosphamide (28) and the phosphoramide mustard (30) 
are detoxified by GST to form 4-glutathionylcyclophosphamide (35) and 
diglutathionylphosphoramide mustard (36), respectively (Dirven et al., 1994). CTX (3) can be 
administered in a wide dosage range, either by oral or intravenous administration. After 
repeated administration, CTX (3) shows to cause auto induction (Crombag et al., 2016), in the 
other words,  CTX (3) induces its own metabolism after repeated administration of several 
consecutives days. Auto induction results in an approximately 2-fold decrease in the 
elimination half-life of CTX (3) and increased formation of its metabolites. This phenomena 
is detectable as soon as 24 h after the beginning of the treatment. The elimination half-life of 
CTX (3) is 5-9 h (De Jonge et al., 2005). After intravenous administration, CTX (3) is 
eliminated primarily by enzymatic oxidation to active and inactive metabolites as mentioned, 
which are mainly excreted in the urine, while 10%-20% of CTX (3) is excreted unchanged in 
the urine and 4% is excreted in the bile (Crombag et al., 2016).  
CTX (3) is a prodrug with low protein binding (24%), which is activated in the liver 
(Crombag et al., 2016) by hepatic microsomal mixed-function oxidases, predominantly by 
CYP P450. CYP P450 isoenzymes involved in the bioactivation of CTX (3) include CYP2A6, 
2B6, 3A4, 3A5, 2C9, 2C18, and 2C19, with 2B6 displaying the highest 4-hydroxylase activity 
(De Jonge et al., 2005). The hydroxylation at the 4-position of the ring by hepatic mixed 
function oxidases yields the primary metabolite of CTX (3) (Scheme 4), 4-
hydroxycyclophosphamide (28), which subsequently originates aldophosphamide (29) [4-
hydroxycyclophosphamide (28) is in equilibrium with its ring-open tautomer 
aldophosphamide (29)]. Aldophosphamide (29) forms acrolein (31) nonenzymatically and the 
active alkylating moiety, phosphoramide mustard (30), which is formed by the spontaneous β-
elimination of acrolein (31) from aldophosphamide (29) (Balis et al., 1983).  In vivo, CTX (3) 
is converted to 4-hydroxycyclophosphamide (28) by hepatic microsomal enzymes but for in 
vitro experiments the use of 4-hydroperoxycyclophosphamide (37) (Scheme 4) is required 
(Levine et al., 1993) due to the in vitro fast conversion of the 4-hydroperoxyclophosphamide 
(37) to the metabolite 4-hydroxycyclophosphamide (28) and then its transformation to 
acrolein (31) (Dorr and Lagel, 1994).    Acrolein (31) may be responsible for the cardiac and 
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pulmonary toxicities and also for the renal damage observed after CTX (3) therapy (Monneret 
et al., 1993). Moreover, the primary metabolites [4-hydroxycyclophosphamide (28) and 
aldophosphamide (29)] can be enzymatically inactivated after oxidation giving 4-
ketocyclophosphamide (32) and carboxyphosphamide (33), the major urinary metabolites of 
CTX (3) (Balis et al., 1983).  
 
Scheme 4 
 
 
In vitro models to study the metabolism of cyclophosphamide. The metabolites like 4-
hydroxycyclophosphamide (28), and/or aldophosphamide (29) (Fenselau et al., 1977),  
phosphoramide mustard (30), acrolein (31), 4-ketocyclophosphamide (32), 
carboxyphosphamide (33), and dechloroethylcyclophosphamide (34) can be formed in 
human/rat liver microsomes with the appropriate co-factors, when incubated with CTX (3) 
(Connors et al., 1974, Ren et al., 1997).  Ren et al., investigated the formation of 4-
hydroxycyclophosphamide (28) and dechloroethylcyclophosphamide (34) from CTX (3) in 
human liver microsomes. In incubations with CYP isoform-selective inhibitors, 4-
hydroxycyclophosphamide (28) was found to be formed primarily by CYP2C9 at lower 
concentration (0.1 mM) and by CYP3A4/5 at high concentrations (0.7 and 5 mM), whereas 
dechloroethylcyclophosphamide (34) was found to be formed primarily by CYP3A4/5 at high 
concentrations (0.7 and 5 mM) (Ren et al., 1997). Connors et al., incubated CTX (3) with rat 
liver microsomes and two cytotoxic intermediates, 4-hydroxycyclophosphamide (28) and 
aldophosphamide (29), were formed and were then transformed into the known in vitro 
metabolite carboxyphosphamide (33). In addition, another metabolite not active in the 
bioassay system (thus, with low cytotoxicity), dechloroethylcyclophosphamide (34) was 
identified. Carboxyphosphamide (33) and 4-ketocyclophosphamide (32) are the principal 
urinary metabolites of CTX (3), but they were found to be non-toxic against Walker tumour 
cells in vitro. Still, in Walker tumour cells, another metabolite with low cytotoxicity, 
dechloroethylcyclophosphamide (34) was identified (Connors et al., 1974). The 
concentrations of carboxyphosphamide (33) and 4-ketocyclophosphamide (32) to kill 75% of 
the studied tumour cells were > 200 µg/mL and 800 µg/ml, respectively. In contrast, 
phosphoramide mustard (30) is markedly toxic and the dose needed to kill 75% of tumour 
cells is low enough (0-5 µg/ml) for it to be considered a toxic metabolite. Acrolein (31) (3-5 
µg/ml), which was detected following microsomal incubation of CTX (3), has been suggested 
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as the antitumour metabolite, but it is not as toxic in the bioassay system involving Walker 
tumour cells as was phosphoramide mustard (30) in the concentrations tested (0-5 µg/ml) 
(Connors et al., 1974). 
Acrolein (31) and 4-hydroperoxycyclophosphamide (37) are roughly equipotent as a 
cardiac cell toxins, in rat cardiac myocytes. The depletion of glutathione is involved in their 
toxic mechanisms. Therefore, to block the toxic effects of both 4-
hydroperoxycyclophosphamide (37) and acrolein (31) in rat myocytes, exogenous sulfhydryl 
containing compounds were used (Dorr and Lagel, 1994).  
The cardiotoxicity of CTX (3) and acrolein (31) was studied in the H9c2 cell line and 
in isolated Langendorff-perfused rat hearts by Nakamura et al. They also investigated the 
cellular toxicity of DOX (1) in the same conditions and models, since DOX (1) is known to 
have cardiac toxicity. It has been found that CTX (3) by itself had no toxic effect, while the 
cytotoxicity of acrolein (31) was 1000 times higher than that of DOX (1) in this cell line. 
Regarding the isolated rat heart, acrolein (31) reduced the left ventricular pressure and heart 
rate and increased the left ventricular end diastolic pressure. No effects were found with CTX 
(3). These results suggest that the cardiac toxicity of CTX (3) may be largely caused by its 
metabolites, namely acrolein (31) (Nakamura et al., 2010). 
 
 
5-Fluorouracil (5-FU) 
 
5-FU (4) is widely used as an antitumour agent for the treatment of solid tumours. It is 
an antimetabolite that acts during the S phase of the cell cycle and is an analogue of uracil 
with a fluorine atom at the C-5 position in place of the hydrogen (Heidelberger, 1975). 5-FU 
(4) is active against various types of cancer, including gastric (stomach), breast, pancreatic, 
colorectal, and head and neck carcinomas (Longley et al., 2003). 5-FU (4) is considered the 
second most frequent cause of cardiotoxicity by anticancer agents, after anthracyclines (Reis-
Mendes et al., 2016b).  
5-FU (4) is administered intravenously. After administration, 5-FU (4) binds weakly to 
proteins, shows a high apparent volume of distribution and is predominantly metabolized in 
the liver, where the DPD plays a crucial role in the deactivation of 5-FU (4) (Crombag et al., 
2016). 5-FU (4) (as the free base) enters into the cells by passive diffusion and is distributed 
throughout the body, including the brain. Less 10 to 15% of the 5-FU (4) is excreted intact in 
the urine but its clearance occurs primarily through hepatic metabolism (Balis et al., 1983). 
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5-FU (4) is metabolized via two routes in competition with each other (Scheme 5): the 
anabolic route, which gives rise to three main active metabolites, fluorodeoxyuridine 
monophosphate (5-FdUMP, 39), fluorouridine triphosphate (5-FUTP, 40), and 
fluorodeoxyuridine triphosphate (5-FdUTP, 41), and the catabolic route, which inactivates 5-
FU (4) and leads to elimination of the drug (Malet-Martino and Martino, 2002, Longley et al., 
2003). The anabolic pathway of 5-FU (4) (Scheme 5) is rather complex, since various parallel 
reactions can occur. 5-FU (4) can react in the following three ways: the first leads in two steps 
to the formation of 5-FdUMP (39); the other two routes form 5-fluorouridine-5′-
monophosphate (5-FUMP, 42). This later molecule may undergo two successive 
phosphorylations to give rise to 5-fluorouridine-5‘-diphosphate (5-FUDP, 43) and 5-
fluorouridine-5‘-triphosphate (5-FUTP, 40). 5-FUTP (40) can be incorporated into the RNA 
instead of uridine-5‘-triphosphate (UTP). 5-FUTP (40) can also form 5-FU-nucleotide sugars 
(5-FUDP-sugars, 44). 5-FdUMP (39) and 5-FUDP (43) can be transformed into 5-fluoro-2‘-
deoxyuridine-5’-diphosphate (5-FdUDP, 45). The latter may then be phosphorylated to 5-
FdUTP (41), which acts as a substrate for DNA polymerase and can thus be incorporated into 
the DNA (Malet-Martino and Martino, 2002). The catabolism (Scheme 5) involves three 
stages: the first stage of degradation occurs very fast under the action of DPD, which reduces 
5-FU (4) to 5,6-dihydro-5-fluorouracil (5-FUH2, 46). DPD is the rate-limiting enzyme in 5-
FU (4) catabolism (Longley et al., 2003). The rate at which 5-FU (4) is available for 
anabolism is set effectively by this first stage. 5-FUH2 (46) is then cleaved to originate α-
fluoro-β-ureidopropionic acid (FUPA, 47) and in a third stage leads to the formation of α-
fluoro-β-alanine (FBAL, 48). FBAL (48) is the major catabolite of 5-FU (4) (Malet-Martino 
and Martino, 2002). An undesirable consequence of the catabolism of 5-FU (4) is the 
diversion into metabolic routes that lead to the formation of the highly myocardiotoxic 
fluoroacetate (49) by scission of the pyrimidine ring  (Arellano et al., 1998). The high 
cardiotoxicity potential of fluoroacetate (49) is due to the fact that fluoroacetate (49) enters 
the Krebs cycle mimicking fluoroacetyl-coenzyme A and is then transformed into 
fluorocitrate (a potent inhibitor of the enzyme aconitase). The inhibition of aconitase by 
fluorocitrate inhibits the utilization of citric acid resulting in the accumulation of intracellular 
citrate (Matsubara et al., 1980). The build-up of citrate in heart leads to a severe impairment 
of cardiac ATP synthesis (Arellano et al., 1998). 
 
Scheme 5 
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 In vitro models to study the metabolism of 5-fluorouracil. The fluoroacetate (49) metabolite of 
5-FU (4) was isolated in perfused rat liver and in the rats’ urine. The levels of fluoroacetate 
(49) found in perfusates of rat livers and in rat urine were low. However, it is known that 
when 5-FU (4) is administrated in a therapeutic dose of 15 mg/kg for several days, 
fluoroacetate (49) accumulates in the body. Therefore, the cardio- and/or neurotoxic effects in 
patients treated with 5-FU (4) can be explained by the cumulative toxicity of fluoroacetate 
(49) that emerges from the catabolic pathway (Arellano et al., 1998). Moreover, it was found 
that the fluoroacetate (49) precursor, FBAL (48), has a prolonged half-life elimination time 
(Heggie et al., 1987) and it  accumulates and is retained in various rat tissues up to 8 days, 
namely in liver, heart, and brain (Zhang et al., 1992). 
The 5-FU (4) metabolism was studied in intact Yoshida sarcoma cells, where 5-FU (4) 
was mainly phosphorylated. In the same work but in liver slices, 5-FU (4) was mainly 
degraded and the degradation of 5-FU (4) was faster in the liver than in other tissues (kidney, 
bone marrow, spleen, heart, lung, thymus, brain, stomach, and muscle) and very slow in the 
tumour tissue (Ikenaka et al., 1979). This rapid/slow degradation depends on the 
polymorphism of the metabolic enzymes involved in 5-FU (4) catabolism.  
 
 
Tyrosine kinase inhibitors (TKIs) 
  
Tyrosine kinases are frequently mutated or amplified in cancer and therefore the 
development of therapeutic tyrosine kinase inhibitors (TKIs) has gained a recent interest since 
tyrosine kinase can be a potential therapeutic target. The current formation of TKIs is 
inherently non-selective and the design of multitargeted TKIs allows a single agent to be more 
effective. These unselective TKIs are used in several types of cancer. Their increase in use 
was accompanied with an increased risk of cardiotoxicity, since the inhibition of ”bystander” 
targets that are involved in cardiomyocyte survival, causes cardiac damage (Force et al., 
2007). Two general classes of target TKIs have been developed: humanized monoclonal 
antibodies directed against the tyrosine kinase receptor such as trastuzumab, pertuzumab, and 
bevacizumab and small-molecule TKIs including imatinib (5), sunitinib (6), and sorafenib (7).  
Monoclonal antibodies have been found to cause cardiotoxicity, and this issue has 
been extensively reviewed (Force et al., 2007, Hudis, 2007, Perez et al., 2008, Nielsen et al., 
2009, Maharsy, 2015). For instance, in a phase III clinical study of trastuzumab efficacy, the 
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addition of trastuzumab to anthracyclines  (DOX (1) or epirubicin) and CTX (3) improved 
survival in women with metastatic breast cancer; however, high cardiotoxicity was an 
unanticipated finding, since 27% of patients treated with the regimen of anthracyclines, CTX 
(3), and trastuzumab developed heart failure (Slamon  et al., 2001).  
After the milestone approval of imatinib (5), in 2001, 35 new small-molecule kinase 
inhibitors were approved. However, several cardiac adverse events are being described with 
TKIs (Lenihan and Kowey, 2013). Recently, the cardiotoxicity of 21 FDA-approved TKIs 
was screened and allowed to stablish a cardiac safety index for TKIs toxicity using human 
induced pluripotent stem cell–derived cardiomyocytes (Sharma et al., 2017). Endothelial cells 
and cardiac fibroblasts were also used in that work. Sorafenib (7), regorafenib (a close-related 
analogue of sorafenib), and ponatinib (withdrawn quickly for serious adverse vascular events) 
were the most cytotoxic TKIs found in this study, thus demonstrating that this approach can 
be important for screening the potential cardiotoxicity of new chemotherapeutic compounds. 
However, the role of their metabolites on the cardiotoxicity is not yet investigated thoroughly. 
Following, targeted therapy associated with cardiotoxicity, focusing on the first approved 
TKIs imatinib (5) and two commonly used vascular endothelial growth factor receptors (VEGFR) 
inhibitors sunitinib (6), and sorafenib (7) and their metabolites are presented.  
 
 
 
Imatinib  
 
Imatinib mesylate or STI571 (imatinib, 5) was the first TKIs anticancer drug of small 
molecules to be approved by the FDA after the International Randomized Study of Interferon 
versus STI571 clinical study that confirmed its potency in the treatment of chronic 
myelogenous leukaemia, while  presenting minimal side effects (Force et al., 2007).  
Imatinib (5) is rapidly and nearly completely absorbed in the gastrointestinal tract after 
oral administration. Maximum (peak) plasma concentration values (Cmax) after single and 
multiple doses are achieved within 1–2 h. The main phase I metabolic pathways (Scheme 6) 
identified for this compound were: CGP74588 (52, main metabolite, N-demethylation), 
AFN911 (53, benzylic hydroxylation), CGP72383 (54, pyridine N-oxidation), CGP71422 (55, 
piperazine-N-4-oxidation), M28.8 (56), M29.6 (57), APG050 (58), APG049 (59, piperazine 
ring oxidation with lactam formation), and M42.2 (60, oxidative deamination and rapid 
oxidation of the intermediate aldehyde to a carboxylic acid). Direct conjugation of imatinib 
JU
ST
 AC
CE
PT
ED
(5) and of the N-demethyl metabolite CGP74588 (52) with glucuronic acid, most probably at 
the nitrogen atom, and glucuronidation of the oxidative metabolites CGP74588 (52), APG050 
(58), M29.6 (57), and M28.8 (56) are pathways of phase II metabolism (Gschwind et al., 
2005). 
Imatinib (5) inhibits the tyrosine kinase activity of the BCR-ABL fusion protein 
resulting from a chromosomal translocation, known as the Philadelphia chromosome (Ph). 
The BCR-ABL fusion protein dimerization phosphorylates the ABL kinase domain leading to 
its constitutive activation. This constitutively active kinase triggers antiapoptotic pathways 
(RAS-ERK, PI3K-AKT, JAK-STAT), thus enhancing cell division and inhibiting DNA 
repair, therefore leading to chronic myelogenous leukaemia (Goldman  and Melo 2003). In 
addition to the inhibition of BCR-ABL, the lack of specificity of the anticancer drug imatinib 
(5) enables it to be used for gastrointestinal stromal tumours, where its target is the c-kit 
kinase (Kerkelä et al., 2006).  
Imatinib (5) blocks all BCR–ABL dependent phosphorylation and signalling events, 
which leads to reversal of the pro-survival effects and activation of apoptosis in chronic 
myeloid leukaemia progenitor cells. The BCR–ABL kinase is on plasma membrane or 
endoplasmic reticulum of cardiomyocytes and seems to be responsible to preserve 
endoplasmic reticulum homeostasis. The BCR–ABL kinase inhibitor, imatinib (5), causes 
endoplasmic reticulum stress, with activation of several noxious pathways that ultimately lead 
to BAX release followed by mitochondrial depolarization, ATP depletion, cytochrome c 
release, and features of necrotic and apoptotic cell death in the heart (Force et al., 2007). 
Fernández and collaborators performed molecular modifications to imatinib (5) to achieve 
three objectives: guide to the primary impact on c-kit kinase, reduce the inhibitory impact on 
BCR-ABL kinase (which has been linked to the cardiovascular side effects of the drug), and 
promote inhibition of an additional target, JNK, to reinforce the prevention of cardiotoxicity. 
A new derivative named WBZ_4 (61) (Figure 2) caused a decrease of tumour volume and 
weight in a mouse model of gastrointestinal stromal tumours to a similar extent to that 
observed with imatinib (5). In contrast to imatinib (5), this new compound did not affect left-
ventricular cardiac function, contributing to that lack of cardiotoxicity the reduced activation 
of JNK in cardiomyocytes (Fernández et al., 2007).  
It was recently demonstrated that the upregulation of Bcl-2, an anti-apoptotic protein, 
protects against imatinib (5)-induced cardiotoxicity and that this cardiotoxicity is age-
dependent. It is also important to point out that cardiac toxicity could be latent, as seen with 
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anthracyclines, where cardiac dysfunction can occur years after the end of drug therapy 
(Maharsy et al., 2014).  
 
Scheme 6 
 
In plasma, urine, and faeces from four healthy male volunteers to whom were given a 
single 239-mg oral dose of imatinib mesylate, unchanged imatinib (5) and its N-demethyl 
metabolite CGP74588 (52) were the most prominent components in all of the investigated 
matrices (Gschwind et al., 2005). Imatinib (5) was metabolized to the active anticancer 
metabolite CGP74588 (52) (Scheme 6) by CYP3A4 and CYP3A5 and, to a lesser extent by 
CYP2D6 (van Erp et al., 2007). In a recent study, it was demonstrated that the demethyl 
metabolite, CGP74588 (52), was substantially less active than imatinib (5) in cell-based 
assays, both as an inhibitor of BCR-ABL and of c-kit kinases. Consequently, to improve the 
pharmacokinetic profile and hence efficacy of imatinib (5), the N-trideuteromethyl analogue 
(62) of imatinib (5) (Figure 2) was administrated in the rat via intravenous route. The N-
trideuteromethyl analogue (62) showed a similar potency to that of imatinib (5) as an inhibitor 
of the tyrosine kinase activity of BCR-ABL and of c-kit kinases, and this was translated into 
similar degrees of efficacy against cell proliferation. In the same work, Manley et al. 
demonstrated that the imatinib metabolite APG050 (58) was devoid of kinase activity at 
concentrations <3000 nM (Manley et al., 2013). 
 
Figure 2 
 
In vitro models to study the metabolism of imatinib. In vitro metabolism of imatinib (5) in rat 
and human liver microsomes showed that imatinib (5) formed two major metabolites in the 
presence of NADPH: N-demethyl imatinib metabolite CGP74588 (52) and the oxidative 
metabolite, CGP71422 (55), via N-oxidation of the piperazine ring. This incubation also leads 
to the formation of other metabolites (Scheme 6), such as AFN911 (53), M28.8 (56) and 
M29.6 (57) (Ma et al., 2009). Still, in rat and human liver microsomes, three new conjugates 
(63-65) (Scheme 6) were detected that resulted from addition of 621 atomic mass units (amu), 
corresponding to adenine dinucleotide phosphate (ADP
+
), to the N-demethyl metabolite 
CGP74588 (52), imatinib (5), and imatinib N-oxide (55) respectively, in the presence of 
NADPH. The major metabolite (64) was detected, which corresponds to adenine dinucleotide 
phosphate (ADP
+
) conjugate of imatinib (ADP
+
 adduct of imatinib). The conjugation 
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occurred between the pyridine nitrogen of imatinib and the ribose ring of ADP
+
 moiety. With 
the incubation with human liver microsomes, ADP
+
 adducts of imatinib (64) was the major 
metabolite detected (Ma et al., 2008). However, the same authors in a later work and also 
using human liver microsomes, only detected two major metabolites CGP74588 (52) and 
CGP71422 (55) (Ma et al., 2009). These dissimilar outcomes can be the result of different 
human donors and therefore different enzymatic abilities of the microsomes. 
Several imatinib metabolites were produced when imatinib (5) was incubated with 
insect-cell microsomes. Those metabolites were attributed to one demethylated and six N-
oxide- or hydroxy metabolites (Marull and Rochat, 2006). The metabolism of imatinib (5) 
was also investigated in rat and human liver microsomes, whose products were researched by 
atmospheric pressure chemical ionization (APCI) mass spectrometry (MS) to distinguish 
hydroxyl metabolites from N-oxides of imatinib because N-oxides are known to undergo 
deoxygenation during APCI.  In rat liver microsomes, the formation of nine major metabolites 
was observed: four oxidative metabolites [AFN911 (53), CGP71422 (55), (66), and (67)], a 
N-desmethyl metabolite (CGP74588, 52), a N-demethylation followed by oxidation 
metabolite (68), and three novel conjugates (63, 64, and 65) resulting from 621 amu addition 
to N-desmethyl imatinib (CGP74588, 52), imatinib (5), and imatinib N-oxide (CGP71422, 
55), respectively.  
 
 
Sunitinib 
 
Sunitinib (6), a multitargeted tyrosine kinase inhibitor, which was approved by both 
US and European Commission regulatory agencies for clinical use, extends survival of 
patients with metastatic renal-cell carcinoma and gastrointestinal stromal tumours, but 
concerns have been raised about its cardiac safety (Mellor et al., 2011). 
Sunitinib (6) inhibits VEGFRs, platelet-derived growth factor receptors (PDGFR), the 
stem cell factor receptor, and c-kit. It causes cardiotoxicity in treated cancer patients 
(Maharsy, 2015). Its broad number of targets makes it hard to identify the exact mechanisms 
of sunitinib (6) toxicity when compared with other more selective kinase inhibitors; sunitinib 
(6) inhibits at least 50 kinase targets at therapeutically relevant concentrations in in vitro 
assays (Force and Kolaja, 2011).  
After oral administration, sunitinib (6) is slowly absorbed in the gastrointestinal tract, 
reaching the Cmax in about 6–12 h in both healthy subjects and cancer patients. 
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Approximately 95% and 90% of sunitinib (6) and SU12662 (69), its metabolite, (Scheme 7) 
are bound to plasma proteins, respectively (Di Gion et al., 2011). The terminal half-lives of 
sunitinib (6) and SU12662 (69) are approximately 40 to 60 h and 80 to 110 h, respectively. 
Renal elimination plays a minor role in the clearance of  sunitinib (6), therefore renal 
impairment will not have a significant effect on its pharmacokinetics (Khosravan et al., 2010). 
The metabolite SU12662 (69) is present in the urine of human, monkey, and rat subjects 
treated with sunitinib. The metabolite M3 (70) is a minor metabolite that was excreted in 
urine and faeces (Scheme 7). M4A, C, and D (71) are minor metabolites observed in faeces. 
Minor metabolites M5A and B (72) were excreted in both rat urine and faeces.  M6 (73) was a 
minor metabolite detected in rat and monkey faeces. M8 (74) was a major metabolite in rat 
and monkey faeces. M9 (75) was a minor metabolite excreted in rat and monkey faeces. 
Metabolite M10 (76) was a minor metabolite only observed in monkey faeces (Speed et al., 
2012). 
Contradictory data regarding the cardiotoxicity of sunitinib exist. In one study, in 
patients that used the recommended therapeutic dose of 50 mg/day, sunitinib (6) displayed a 
manageable toxicity and no cardiac adverse events were reported (Faivre et al., 2006). 
However, in another study, 15% of the patients treated with sunitinib (6) developed 
symptomatic grade 3/4 heart failure, with increased risk of cardiotoxicity among older 
patients and women, among patients with a prior history of coronary artery disease and 
congestive heart failure and in patients with a lower body mass index (Telli et al., 2008). It 
has been shown that sunitinib (6) increased blood pressure and almost half of the treated 
patients (47%) developed hypertension (Chu et al., 2007). Sunitinib (6)-induced hypertension 
has an important role in its cardiotoxicity; however, additional mechanisms may be involved, 
since several patients who developed cardiotoxicity after sunitinib (6) did not had any sings of 
hypertension (Force and Kolaja, 2011). In treated patients, sunitinib (6)-induced cardiac 
dysfunction was associated with abnormal histopathological changes such as myocyte 
hypertrophy and changes in mitochondrial structure. Sunitinib (6) targets mitochondria in 
cultured rat cardiomyocytes, leading to cytochrome c release into the cytosol. This release can 
activate the mitochondrial pathway for apoptosis. Sunitinib (6) induces cardiomyocyte 
apoptosis with activation of caspase-9, an initiator caspase of the mitochondrial apoptotic 
pathway (Chu et al., 2007). The gathered data is clear in the message that physicians treating 
patients with sunitinib (6) must be very careful, especially in patients with pre-existing 
cardiovascular risk factors, like hypertension, history of cardiac disease, or previous treatment 
with other cardiotoxic agents (Orphanos et al., 2009). 
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Speed and colleagues studied [
14
C]sunitinib (6) metabolism in rats, monkeys, and 
humans (Scheme 7) and demonstrated that sunitinib (6) was extensively metabolized in the 
three species primarily via the oxidative metabolism pathways mediated by CYP P450s. 
Many metabolites were detected both in urine and faeces extracts but faecal excretion (61%) 
was the major route of elimination of the dosed radioactivity in the three species. Several 
putative structures (69-82) of sunitinib metabolites were proposed in this study (Scheme 7) 
(Speed et al., 2012). The main metabolic pathways were N-de-ethylation and hydroxylation of 
indolylidene/dimethylpyrrole. Radiochemical metabolite profiles of plasma samples from the 
three species showed two major radioactive peaks corresponding to sunitinib (6) and N-de-
ethyl-sunitinib (SU12662, 69) (Speed et al., 2012).  SU12662 (69) was the major active 
metabolite.  Pharmacokinetic/pharmacodynamic data from animal studies showed that target 
plasma concentrations of sunitinib (6) plus SU12662 (69) capable of inhibiting PDGFR- and 
VEGFR-2 phosphorylation were established in the range of 50 to 100 ng/mL.  
 
Scheme 7  
 
CYP3A4 was demonstrated to be the major human CYP P450 isoform to catalyse the 
formation of SU12662 (69), which is then further metabolized to inactive compounds by the 
same enzyme (Di Gion et al., 2011, Speed et al., 2012).  
 
 
In vitro models to study the metabolism of sunitinib. The identification of metabolites in vitro 
of sunitinib (6) was performed in liver microsomes from mice, rats, dogs, monkeys, and 
humans. SU12662 (69) was the major metabolite found in mice, monkeys, and human liver 
microsomes, while M2E (77) was the predominant metabolite in dog liver microsomes. The 
metabolite SU12662 (69) predominated at a higher substrate concentration (25 μM), but M2E 
(77) was the major metabolite at a low concentration (2 μM), in rat liver microsomes. Still, in 
vitro metabolism studies showed that the SU12662 (69) metabolite and sunitinib (6) were 
equipotent in biochemical tyrosine kinase inhibition and cellular proliferation assays, acting 
on VEGFR, PDGFR, and c-kit (Speed et al., 2008). 
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Sorafenib 
 
Sorafenib (7) is another multitargeted TKI against VEGFR 2 and 3, PDGFR b, c-kit, 
FMS-like tyrosine kinase-3 (Flt3 or CD135), RAF1 (or CRAF), and BRAF (Orphanos et al., 
2009). It is approved for the treatment of hepatocellular carcinoma, advanced renal cell 
carcinoma, and differentiated thyroid carcinoma (Anon, 2015).  The underlying pathways of 
sorafenib (7)-induced cardiotoxicity are not clear and several questions are still to be 
answered. Sorafenib (7) inhibits the RAF1 and BRAF kinase activity. These pathways are 
believed to have an important role in cell survival in the heart. Sorafenib (7) was hypothesized 
to disrupt the RAF1–MST2 protein–protein interaction, activating three proapoptotic 
mediators: Jun N-terminal kinase (JNK), forkhead box O (FOXO) and large tumour 
suppressor, homologue 1 (LATS1). On the other hand, if sorafenib inhibits RAF1–ASK1 
interaction, it will lead to activation of JNK, JNK-mediated phosphorylation of 14-3-3 
proteins and release of BAX, which would lead to mitochondrial cytochrome c release and 
cell death (Force et al., 2007). Recently, patient-specific human induced pluripotent stem 
cells-derived cardiomyocytes (hiPSC-CMs) were used to screen TKIs for cardiotoxicity by 
evaluating cardiomyocyte viability, contractility, electrophysiology, calcium handling, and 
intracellular signalling (Sharma et al., 2017). Sorafenib (7) induced the highest cell death in 
hiPSC-CMs, with median lethal dose (LD50) value of 3.4 M and with safety indices 
comparable to those of DOX (1). Sorafenib (7) elicited a compensatory increase in 
cardioprotective insulin/IGF1 signalling (phosphorylation) in hiPSC-CMs. A twofold increase 
in the expression of neuropilin 2, a noncanonical VEGFR and an up-regulation of KDR 
(VEGFR2 receptor) and an up-regulation in the expression of VEGF ligands led the authors to 
hypothesize that hiPSC-CMs may compensate for VEGFR2 signalling loss by upregulating 
auxiliary VEGFR expression, thus facilitating VEGF signalling in the absence of VEGFR2 
kinase activity (Sharma et al., 2017).  
Sorafenib (7) is known to induce acute coronary symptoms including myocardial 
infarction in 2.9% of patients. Sorafenib (7) is often administrated after sunitinib (6) therapy 
(Orphanos et al., 2009). In phase I trials, was observed hypertension in 5-11% of the treated 
patients (Strumberg et al., 2007) while in another study hypertension was reported in 17% of 
the patients (Escudier et al., 2007).  
Sorafenib (7) is administered orally and it is rapidly absorbed resulting in Cmax in 
approximately 3 h.  Sorafenib (7) is mainly metabolized in the liver by CYP3A4, as well as 
by glucuronidation mediated UGT1A9. Sorafenib (7) conjugates may be cleaved in the 
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gastrointestinal tract by the bacterial glucuronidase activity, allowing reabsorption of the 
unconjugated active substance. In vitro, 99.5% of sorafenib (7) is bound to human plasma 
proteins (Anon, 2015). 
Eight metabolites (83-90) of sorafenib (7) (Scheme 8) have been identified, of which 
five were detected in plasma, M-2 (83), M-4 (84), M-3 (85), glucuronide of sorafenib (86), 
and carboxylic acid of sorafenib (87), three in the faeces, M-4 (84), M-3 (85), and carboxylic 
acid of sorafenib (87), and two in urine, glucuronide of sorafenib (86) and carboxylic acid of 
sorafenib (87). The main circulating metabolite of sorafenib (7) in plasma, the N-oxide (M-2, 
83), has a similar in vitro potency to that of sorafenib (7). Sorafenib (7) has an elimination 
half-life of 25 - 48 h. Following oral administration of sorafenib (7), 77% of the dose was 
excreted in faeces and 19% of the dose was excreted in urine as glucuronidated metabolites. 
Unchanged sorafenib (7), accounting for 51% of the dose, was found in faeces but not in 
urine, indicating that biliary excretion of the unchanged active substance might contribute to 
the elimination of sorafenib (7) (Anon, 2015).  
The metabolites M-2 (83), M-4 (84), and M-5 (88) of sorafenib (7) are potent 
inhibitors of several tyrosine kinase receptors, namely VEGFR-2, PDGFR-β, and Flt-3. Two 
of the metabolites, M-2 (83) and M-5 (88) were even more potent than sorafenib (7) at 
inhibiting PDGF-dependent human aortic smooth muscle cell proliferation. However, 
sorafenib (7) was more potent than M-2 (83) or M-5 (88) against RAF1. Sorafenib (7) was 
also significantly more potent against Flt-3 than M-5 (88). The three metabolites [M-2 (83), 
M-4 (84), and M-5 (88)] had similar in vitro pharmacological activity against VEGFR-2, 
PDGFR-β, and Flt-3 as sorafenib (7) but the metabolites have much lower plasma levels in 
vivo. The most predominant human metabolite, M-2 (83), was also evaluated in vivo for its 
antitumour efficacy and data indicated that M-2 (83) was effective when administered orally 
at a dose level of 120 mg/kg against the MDA-MB-231 xenograft model, a model of human 
breast cancer (Anon, 2006). No assessment of the potential cardiotoxicity of metabolites was 
done so far, to the best of our knowledge. 
 
Scheme 8 
 
 
In vitro models to study the metabolism of sorafenib. Two major metabolites were identified 
using human liver microsomes: the metabolite M-2 (83), originated after oxidation of the 
pyridine nitrogen and metabolite M-3 (85) by oxidation of the terminal amido methyl group. 
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In this system, the formation of M-4 (84) metabolite also occurred, with relative formation of 
the M-2 (83): M-3 (85): M-4 (84) metabolites being established in the ratio of 65:34:1 
(Ghassabian et al., 2012). 
 
 
Prodrugs  
 
The use of prodrugs is a strategy to overcome the undesirable properties of drugs and 
to enhance therapeutic efficacy (Han and Amidon, 2000). The use of the prodrug concept can 
allow increasing or decreasing the solubility of a drug, masking taste or odour problems, 
reduction of pain or irritation at injection sites, enhancement of chemical stability, 
enhancement of oral absorption, prolongation of drug action, reduction in toxicity, and 
achieving site-specific drug delivery. However, these advantages bring some disadvantages 
for prodrugs: among others, if a very water-soluble prodrug is not rapidly converted to the 
parent drug after administration, it may be significantly and rapidly eliminated in the urine, 
thereby reducing drug bioavailability. In addition, the possibility of prodrug accumulation in 
the body occurs, particularly in patients with impaired renal function (Stella et al., 1985). 
There are many intrinsic and extrinsic factors that can influence the bioconversion of 
prodrugs. The activity of many enzymes responsible for the activation of the prodrugs may be 
decreased or increased due to genetic polymorphisms, age-related physiological changes, drug 
interactions, or interspecies variations leading to adverse pharmacokinetic, pharmacodynamic, 
and clinical effects. The genetic polymorphisms of prodrug activation contribute to the 
variability in prodrug activation and thus to the efficacy and safety of drugs. Nevertheless, in 
some cases, the development of a prodrug may be an attractive strategy for anticancer drug 
design, rather than searching for a new active agent with suitable ADMET properties 
(Huttunen et al., 2011). The reason for the pro-drug study in this review is to determine if this 
strategy had any success in decreasing cardiotoxicity or only in improved pharmacokinetics of 
anticancer drugs. 
 
 
Prodrugs of DOX (1) 
 
By using endogenous and exogenous enzymes and the prodrug design, it was possible 
to minimize the dose-related toxic side effects of DOX (1) and improve the delivery of the 
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drug to the targeted tumour cells (Rollas and Küçükgüzel, 2008). Among DOX (1) prodrugs 
developed, the cephalosporanic acid based prodrugs (Hudyma et al., 1993), hydrazine and 
amide prodrugs, and carbamate prodrugs stand out (Rollas and Küçükgüzel, 2008). Two 
DOX(1)–HPMA (N-(2-hydroxypropyl)methacrylamide) copolymer conjugates (PK1 and 
PK2) and an acid-sensitive albumin-binding prodrug (aldoxorubicin, 91) have been assessed 
clinically (Figure 3A). The first drug–polymer conjugate to enter clinical trials was PK1 
(Figure 3A) (Kratz et al., 2007). 
 
Figure 3 
 
 
Aldoxorubicin (91) (Figure 3B) is conjugated to a linker (an acid-sensitive hydrazine 
moiety), a 6-carbon spacer, and a thiol-binding maleimide (6-maleimidocaproic acid 
hydrazide). Aldoxorubicin (91) also is derivatized at C-13-keto position (Mita et al., 2015). 
Aldoxorubicin (91) binds rapidly and covalently to the cysteine-34 amino acid of endogenous 
albumin, when it enters the bloodstream. This prodrug strategy has several advantages, among 
which stands out the cancer chemotherapy improvement. Aldoxorubicin (91) rapidly binds to 
the cysteine-34 position of endogenous albumin and the release of the albumin-bound drug in 
the acidic environment at the tumour site occurs. This is accomplished by the incorporation of 
an acid-sensitive bond between the drug and the carrier. Due to the enhanced vascular 
permeability and poor lymphatic drainage that are main characteristics of tumours, albumin-
bound DOX (1) accumulates in the tumour and is then released in the acidic environment of 
the tumour or inside tumour cells. This release occurs via cleavage of the acid-sensitive 
hydrazine bond between the drug and the linker (Kratz et al., 2002). Aldoxorubicin (91) 
shows a mean circulating half-life of about 20.1–21.1 h, a narrow mean volume of 
distribution and a slow mean clearance rate. These pharmacokinetic characteristics suggest 
that aldoxorubicin (91) is stable in circulation and does not accumulate to a substantial degree 
in body compartments outside of the bloodstream, even if it is or not bound to serum albumin. 
Almost all DOX (1) in circulation remains bound to albumin via the acid-sensitive linker and 
little free DOX (1) is released in the bloodstream. This is one major advantage of the covalent 
bond formed between aldoxorubicin (91) and serum albumin, since that the drug release only 
occurs upon transport to an acidic environment such as the one found at the tumour site. DOX 
(1) is excreted in the urine mostly as unmetabolized drug, reinforcing again the conclusion 
that after administration of aldoxorubicin (91), very little DOX (1) is released into the 
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circulation (Mita et al., 2015). Toxicological studies performed in mice, rats, and dogs 
showed a 3- to 5-fold increase in the maximum tolerated dose, moderate and reversible 
myelosuppression, no liver toxicity and immunotoxicity, and no new toxicity when compared 
with DOX (1) (Kratz et al., 2007). In a rat model, aldoxorubicin (91) has shown to be 
significantly less cardiotoxic at equitoxic dose [(1.1 mg/kg) when compared with DOX (1) 
(0.8 mg/kg weekly for 7 weeks)] (Lebrecht et al., 2007). In fact, the chronic mitochondrial 
and myocardial toxicity of aldoxorubicin (91) in rats is reduced, when compared with free 
DOX (1) (Kratz, 2007, Lebrecht et al., 2007). The lack of observed cardiotoxicity may be due 
to the fact that very little DOX (1) and its major metabolite DOXol (8) (which has been 
implicated in DOX (1) associated cardiotoxicity) are excreted in urine (Mita et al., 2015).  
Because of all of the above, aldoxorubicin (91) was selected for clinical evaluation. In 
a phase I study, no patients had any clinical signs of congestive heart failure, even among 
patients treated at the higher dose levels and/or for extended periods (Unger et al., 2007). 
Aldoxorubicin (91) can be administered at doses several-fold higher than DOX (1) without 
associated acute cardiotoxicity (Mita et al., 2015). Aldoxorubicin (91) was able to induce 
tumour regression in tumour types known to be anthracycline-sensitive tumours, namely, 
breast cancer, small cell lung cancer, and sarcoma. However, in tumours like prostate and 
kidney cancer, tumours known to not being sensitive to anthracyclines (Unger et al., 2007), 
no significant tumour regression or tumour control was shown after aldoxorubicin (91) 
administration. Aldoxorubicin (91) is currently under investigation in larger clinical studies 
that involve patients with soft tissue sarcoma or other anthracycline-sensitive cancers (Chawla 
et al., 2015). 
 
 
Prodrugs of 5-FU (4) 
 
5-FU (4) shows nonspecific cytotoxicity for tumour cells, it loses efficiency because 
of its poor distribution to tumour sites, and its effectiveness is limited due to drug resistance 
(Malet-Martino and Martino, 2002). Therefore, new therapeutic strategies were needed. To 
improve the physicochemical, biopharmaceutical, and pharmacokinetic properties of 5-FU 
(4), several derivatives have been synthesized and some of these have found a place in the 
clinical practice. Their main benefit is the possibility of oral administration taking as example 
the capecitabine (CAP, 92) prodrug (Scheme 9) (Daumar et al., 2011). 
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CAP (92) is a fluoropyrimidine and it was a developed antineoplastic prodrug of 5-FU 
(4) with enhanced tumour selectivity. When CAP (92) is orally administered, it crosses the 
gastrointestinal barrier intact and is rapidly and almost completely absorbed (Malet-Martino 
and Martino, 2002). Due to its efficacy, easier administration, and milder toxicity profile 
compared with 5-FU (4), CAP (92) has gained popularity (Ang et al., 2010). In the body, it is 
first metabolized in the liver by carboxylesterase to 5-deoxy-5-fluorocytidine (5-dFCyd, 93) 
and it is latter converted to 5-deoxy-5-fluorouridine (5-dFUrd, 94) by cytidine deaminase 
(Cyd deaminase) in the liver and tumour tissues (Scheme 9). This enzyme is mainly located in 
the liver and tumour tissues. 5-dFUrd (94) is converted to the active drug, 5-FU (4) by 
thymidine phosphorylase (dThdPase), which is present at higher concentrations in tumour 
tissues. Carboxylesterase, Cyd deaminase, and dThdPase are three enzymes essential for the 
clinical efficacy of CAP (92) (Miwa et al., 1998).  
This prodrug was designed to limit plasma concentrations of 5-FU (4) by allowing it to 
be selectively bioactivated in the tumour, since the concentrations of 5-FU (4) in plasma do 
not reflect the exposure of the tumour tissues to 5-FU (4) because of the absent enzymatic 
activation in normal tissues (Gieschke et al., 2003). CAP (92) has two main advantages, 
which translate into an improved therapeutic index: increased concentration of the active 
principle at the tumour site, and decreased concentration of the drug in healthy tissues with a 
consequent reduction in systemic toxicity (Malet-Martino and Martino, 2002).  
Cardiotoxicity of CAP (92) has been poorly reported, which may suggest that the 
incidence of cardiotoxicity of CAP (92) may be lower than the 1.5–2% reported for 5-FU (4), 
but reach up to 35% (Reis-Mendes et al., 2016b). In 2002, a patient, during treatment with 
CAP (92) developed a severe and prolonged acute coronary syndrome. This patient had 
developed similar symptoms during treatment with 5-FU (4) given by infusion  (Frickhofen et 
al., 2002). In fact, CAP (92) should be considered an agent with cardiotoxic potential and the 
patients with symptoms suggestive of cardiotoxicity should not be treated with CAP (92). In 
another study, a patient experienced chest pain after 96 h following the initiation of CAP (92) 
therapy. They assumed that delayed cardiotoxicity may occur due to cumulative dose effect of 
5-FU (4) or its metabolites after administration of CAP (92) (Senturk et al., 2009). 
 
Scheme 9 
 
CAP (92) was approved by the US FDA for use as a chemotherapy agent, when 
single-agent fluoropyrimidine therapy is preferred, namely in patients with metastatic 
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colorectal cancer. The drug was also approved for use in metastatic breast cancer patients 
(Walko and Lindley, 2005). CAP (92) is also approved to be used to treat metastatic breast 
cancer that does not respond to other chemotherapy (NIH, 2013). However, safety data from 
clinical trials reveal that the toxic profile of CAP (92) is similar to its parent 
fluoropyrimidines (Wijesinghe et al., 2006).   
 
 
Prodrug of sunitinib  
 
There are many toxic side effects associated with sunitinib (6) that limit its therapeutic 
use despite patient’s good response to the multi-targeted TKIs. So, to improve the therapeutic 
index of sunitinib (6), prodrugs that modify the pyrrole group and are able to mimic the 
tyrosine kinase receptor inhibition activity of sunitinib (6) were synthesized. Initially, Huang 
et al. synthesized the bioprecursor AST-001 (95, Figure 4), which showed good proprieties: 
inhibited cancer cell growth in vitro with a potency similar to that of sunitinib (6) and showed 
lower sunitinib (6) concentrations in multiple non-target organs when compared with 
sunitinib (6). However, AST-001 (95) was very unstable and rapidly hydrolysed. For this 
reason, synthesis of more stable compounds like AST-002 (96) and AST-003 (97) were 
generated (Figure 4). In vitro in plasma, AST-002 (96) and AST-003 (97) can be hydrolysed 
to sunitinib (6). The esterase inhibitor, paraoxon, can completely block that hydrolysis, 
suggesting that AST-002 (96) and AST-003 (97) can be efficiently hydrolysed by esterases in 
vivo. In the A549 cancer cell line, a decrease in the phosphorylation of STAT3 and AKT was 
observed after incubation with those metabolites, which revealed a similar effect to of 
sunitinib (6) (Huang et al., 2015). Moreover, AST-002 (96) and AST-003 (97) kill cancer 
cells more rapidly than sunitinib (6) leading to rapid changes in cell morphology after a 8-h 
incubation. The cells incubated with sunitinib (6) remained attached, elongated, and exhibited 
a normal healthy cell morphology, while the cells that were incubated with AST-002 (96) or 
AST-003 (97) appeared round and stressed. Moreover, in a xenograft mice, AST-003 (97) 
exhibited better efficacy due to its faster cell killing effect than sunitinib (6). Moreover, 
enzymes associated with cardiac, liver, and renal functions were less affected by AST-003 
(97) suggesting overall decreased toxicity of AST-003 (97). This prodrug is rapidly 
hydrolysed in vivo into hydroxyl-methyl sunitinib (AST-004, 98) and then to sunitinib (6) 
(Scheme 10). The unique properties of AST-003 (97) suggest that it may have a better 
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therapeutic index than sunitinib (6) in cancer therapy. The therapeutic effects of AST-003 
(97) in humans have not yet been tested (Huang et al., 2015). 
 
Figure 4 
 
Scheme 10 
 
 
Synthesis of anticancer drug metabolites 
 
The models previously mentioned are used for the isolation of metabolites and these 
can be identified by several techniques such as nuclear magnetic resonance and mass 
spectrometry, usually by chromatographic techniques combined with on-line detection. The 
metabolites can be identified from biological fluids such as plasma, urine, or faeces. 
However, the metabolites are often present at low concentrations in biological fluids, and 
chemical synthesis emerges in this scenario as a valuable approach because metabolites are 
then obtained in amounts necessary for research activity/toxicity assays (Venn, 2008). The 
synthesis of metabolites may be done by classical synthesis using total or semi-synthesis or 
metabolic enzymes. The use of the enzymatic methods in the synthesis of drug metabolites 
allows in one step, by a biomimetic synthesis, to obtain the drug metabolites using the same 
biotransformation reaction that occurs in vivo. Similar to classical synthesis, the metabolite 
can be obtained with high purity and its identity can be confirmed in biological matrices. 
However, this biomimetic method for predicting metabolites is not always accurate; it is very 
specific for each metabolite and is also very time consuming.  
The next section describes the synthetic procedures used to obtain metabolites of 
anticancer drugs DOX (1), MTX (2), CTX (3), 5-FU (4), imatinib (5), sunitinib (6), and 
sorafenib (7). The purpose of the syntheses of these metabolites is to further investigate if 
they have any antitumour activity and to evaluate their potential toxicity, namely 
cardiotoxicity. In most of the studies, the metabolites were chemically obtained and then 
isolated using diverse purification procedures. Nevertheless, in some cases, the crude product 
was used in biological studies without further purification. Most of the syntheses involved 
chemical reagents, but in conjugations, enzymes are more frequently applied. Table 2 
highlight the synthetic methods and main products obtained applied to anticancer drugs 1-4, 
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respectively. Only with pure metabolites are obtained can their pharmacological and 
toxicological aspects be accurately studied. 
 
 
Synthesis of DOX (1) metabolites  
 
In Table 2, methods applied in the synthesis of DOX (1) metabolites are firstly 
summarized. DOXol (8) was obtained by reducing the carbonyl group of DOX (1) and 7-
deoxydoxorubicinol aglycone (10) was formed from DOX (1) hydrochloride by catalytic 
hydrogenation. The metabolite 7-deoxydoxorubicin aglycone (11) was synthesized from 
reductive glycosidic cleavage of DOX (1) also by catalytic hydrogenation. 
Demethyldeoxydoxorubicinol aglycone 4-O-sulfate (12) and demethyldeoxydoxorubicinol 
aglycone 4-O-β-glucuronide (13) were obtained from DOX (1) by conjugation with sulfate or 
β-glucuronate, respectively, nearly equally in 4-O-position. The 7-hydroxydoxorubicinol 
aglycone (14) was obtained from 7-hydroxydoxorubicin aglycone (9) using the same 
procedures as described for DOXol (8) but with half quantities of all reactants. All 
metabolites of DOX (1) obtained were purified by thin-layer chromatography (Takanashi and 
Bachur, 1976). 
 
Table 2 
 
 
Synthesis of MTX (2) metabolites  
 
In the synthesis of MTX (2) metabolites (Table 2, entries 8-11), the mono- (16) and di- 
(17) carboxylic acid were synthesized from the 2,3-dihydro-1,4,5,8-tetrahydroxy-9,10-
anthracedione scaffold (Chiccarelli et al., 1986), while glutathione conjugate (19) and the 
cyclic naphthoquinoxaline (20) were formed starting from MTX (2) (Blanz et al., 1991). 
MTX (2) and related structures were found to be resistant to reductive enzymatic activation 
since the quinone functional group within its structure is known to be susceptible to 
enzymatic oxidation (Reszka et al., 1986). None of the metabolites were purified (Chiccarelli 
et al., 1986, Blanz et al., 1991)  
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Synthesis of CTX (3) metabolites  
 
In in vitro studies, 4-hydroperoxycyclophosphamide (37) is used as a more stable 
precursor of 4-hydroxycyclophosphamide (28), the biologically activated form of CTX (3) 
(Gamcsik et al., 1999). Table 2 (entries 12-18) highlights the synthesis of this analogue (37) 
as well as of CTX (3) metabolites. The 4-hydroperoxycyclophosphamide (37) is obtained by 
Fenton oxidation reaction of CTX (3) (Struck et al., 1974). The synthesis of metabolites 4-
hydroxycyclophosphamide (28) and aldophosphamide (29) started from 4-
hydroperoxycyclophosphamide (37). The reaction was maintained at 22°C for 90 min to reach 
equilibrium between 4-hydroxycyclophosphamide (28) and aldophosphamide (29) (Manthey 
and Sladek, 1988). The aldophosphamide (29) oxidation originates the inactive 
carboxyphosphamide (33) by ALDH (Ludeman, 1999). Conversion of 4-
hydroxycyclophosphamide (28) to acrolein (31) and phosphoramide mustard (30) proceeds 
via intermediate aldophosphamide (29) (Low et al., 1982). Fragmentation to phosphoramide 
mustard (30) is favourable in aldophosphamide (29) but not in carboxyphosphamide (33) 
because of differences in electronic factors related to enolization and/or resonance. The 
protons α to the carbonyl in an aldehyde are relatively acidic, when compared with those α to 
a carboxylate group, and therefore, aldophosphamide (29) is more susceptible to a base-
catalysed α,β-elimination reaction than is carboxyphosphamide (33) (Ludeman, 1999). The 
phosphoramide mustard (30) was prepared from phenylphosphorodichloridate (Struck et al., 
1994). Acrolein (31) was obtained by the condensation of formaldehyde with acetaldehyde 
(Dumitriu et al., 1993). The 4-ketocyclophosphamide (32) was obtained from bis(2-
chloroethyl)amine (Hill et al., 1970). The metabolite 2-chloroacetaldehyde (38) was 
synthesized from 2-chloroacetic acid (Shaw et al., 1983). 
 
 
Synthesis of 5-FU (4) metabolites  
 
The methods applied in the synthesis of 5-FU (4) metabolites are included in Table 2 
(entries 19-21). The 5-FdUMP (39) was synthesized from 5-FdUrd (51) (Abraham et al., 
1996). 5-FUMP (42) was obtained from 5-FUrd (50) (Fujita et al., 1994). The synthetic route 
to 5-FUH2 (46) occurs from 1,3-bis-(4-methoxybenzyl)-5,6-dihydro-5-fluorouracil (LaFrate 
and Katzenellenbogen, 2007).   
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Synthesis of imatinib (5) metabolites  
 
The metabolite APG050 (58) was synthesized from compound (101) (Manley et al., 
2013) and the metabolite CGP74588 (52) was formed from compound (103) (Kil et al., 2007) 
and their precursors (99-100). The total syntheses of metabolites (52 and 58) are represented 
in Scheme 11. 
 
Scheme 11 
 
 
Synthesis of sunitinib (6) metabolites  
 
The metabolite SU12662 (69) was already synthetized (Elsinghorst and Gütschow, 
2009). The metabolite M8 (74) was obtained from 5-hydroxy-2-oxindole (compound 104) 
(Caballero et al., 2012). The total syntheses of metabolite M8 (74) is represented in Scheme 
12.  
 
 
Scheme 12 
 
 
Synthesis of sorafenib (7) metabolites  
 
The metabolite M-2 (83) was already synthetized from sorafenib (7) and the 
metabolite M-3 (85) was synthesized from M-4 (84) (Pleiss et al., 2006). The metabolite M-4 
(84) was prepared with 4-chloropyridine-2-carboxamide (105) (Ghassabian et al., 2012). The 
syntheses of metabolite M-4 (84) and M-3 (85) are represented in Scheme 13. 
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Conclusions 
 
This review sums up several aspects of the metabolism of frequently used anticancer 
drugs that cause cardiotoxicity. For that, the available data regarding toxicity and potential 
synthetic routes are discussed and summarized. It is of crucial importance to investigate drug 
metabolism and biotransformation, since the metabolites can be responsible for the 
pharmacological and therapeutic actions or, on the other hand, they can cause toxicity. 
Anthracyclines and other cytotoxic drugs and their metabolites cause cardiotoxicity, which 
can lead to cardiac death. Also the new added molecules to the anticancer therapy, TKIs used 
in various types of cancer have a great risk of cardiotoxicity. Contrarily to cytotoxic 
metabolites of anthracyclines and other drugs, which have been largely studied in the past 
decades, TKIs cardiotoxicity is still recent and of the evaluation of their metabolites putative 
cardiotoxicity is scarce. 
To reduce some toxic side effects observed and improve drug delivery to tumour cells, 
the prodrug strategy has been applied to the DOX (1), 5-FU (4) and sunitinib (6) drugs. There 
are many intrinsic and extrinsic factors that can influence the bioconversion mechanisms of 
prodrugs. The activity of many enzymes responsible for the activation of the prodrugs may be 
decreased or increased due to genetic polymorphisms, age-related physiological changes, drug 
interactions, or interspecies variations leading to adverse pharmacokinetic, pharmacodynamic, 
and clinical effects. At present, systemic site-specific delivery by prodrugs is applicable to a 
small number of currently useful therapeutic agents; however, despite of these drawbacks, the 
prodrug development is still of great interest and has several advantages when considering the 
examples in this review. 
The metabolites may be isolated from biological fluids such as plasma, urine and 
faeces. However, in these fluids, the metabolites are present at low amounts and it is 
necessary to call upon synthesis. This work also provides an overview of various methods that 
can be used to obtain and to study metabolites of various anticancer drugs. The use of 
different in vitro techniques for studying drug metabolism in humans is important in the early 
stages of development of new drugs. Among all the in vitro models, the model that is most 
widely disseminated is the microsomes. 
This review also remits to the synthesis of major metabolites of the drugs mentioned to 
obtain the appropriate quantity for further pharmacological/toxicity studies. Most metabolites 
are obtained by total synthesis involving oxidation and reduction reactions and for that 
purpose similar chemical reagents are used. The synthesis of conjugated metabolites occurs, 
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in most cases, by enzyme-mediated reactions. Large amounts of pure metabolites are required 
for the right assessment of their potential cardiotoxicity.  
 Decades after the use of the conventional anticancer drugs, such as DOX (1), MTX 
(2), CTX (3), and 5-FU (5) in the clinical practice, the effect of their metabolites on their 
cardiotoxicity are not fully recognized. With TKIs use emerging, we are still in the early stage 
of metabolism investigation, since studies have focused in pharmacological activity studies 
than in cardiotoxicity studies. Therefore, cardiotoxic effects of TKI metabolites remain to be 
fully elucidated by new research in the coming years. 
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List of Figures Captions: 
 
Figure 1 – Anticancer drugs approached in this work: DOX (1), MTX (2), CTX (3), 5-FU (4), 
imatinib (5), sunitinib (6), and sorafenib (7). 
Figure 2 – Compound WBZ_4 (60) (Fernández et al., 2007) and N-deuteromethyl analogue 
(61) (Manley et al., 2013). 
Figure 3 – A - Prodrugs of DOX (1) that have been assessed clinically. PK1 and PK2 
compounds incorporate galactosamine as a targeting ligand (Kratz et al., 2007). B - 
Aldoxorubicin (90) prodrug of DOX (1) conjugated to a linker hydrazine, a 6-carbon spacer, 
and a thiol-binding maleimide (Chawla et al., 2015). 
Figure 4 – Prodrugs of sunitinib (6) (Huang et al., 2015). 
 
 
Scheme 1 – Biotransformation of drugs and its consequences (Gunaratna, 2000). 
Scheme 2 – Metabolites resulting from DOX (1). AKR – aldo/ketoreductase; CBR – carbonyl 
reductase; a) deglycosylation; b) O-dealkylation; c) sulfation; d) glucuronidation (Takanashi 
and Bachur, 1976, Voon et al., 2013). 
Scheme 3 – Metabolites resulting from MTX (2) ( Mewes et al., 1993, Rossato et al., 2013, 
Reis-Mendes et al., 2016b). 
Scheme 4 – The main metabolites resulting from CTX (3). CTX (3) is extensively 
metabolized in the liver by CYP450 enzymes to active/toxic metabolites [(4-
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hydroxycyclophosphamide (28), aldophosphamide (29), phosphoramide mustard (30), and 
acrolein (31)], and inactive metabolites [4-ketocyclophosphamide (32), carboxyphosphamide 
(33), dechloroethylcyclophosphamide (34), 4-glutathionylcyclophosphamide (35), and 
diglutathionylphosphoramide mustard (36)]. Other enzymes are involved and several non-
enzymatic catalysed reactions occur. CYP – cytochrome P450; GST – glutathione S-
transferase; ALDH - aldehyde dehydrogenase ( Dirven et al., 1994, De Jonge et al., 2005, 
Ekhart et al., 2008, Jamieson et al., 2014).  
Scheme 5 – Intracellular anabolism and catabolism of 5-FU (4). DPD – dihydropyrimidine 
dehydrogenase (Malet-Martino and Martino, 2002, Gross et al., 2008, Jamieson et al., 2014). 
Scheme 6 – Metabolites of imatinib (5) and identified metabolic processes: a) N-
demethylation; b) hydroxylation; c) N-oxidation; d) N-demethylation and oxidation; e) 
oxidation; f) deamination and oxidation. CYP – cytochrome P450 (Gschwind et al., 2005, Ma 
et al., 2008, van Erp et al., 2009). 
Scheme 7 – Proposed pathways for metabolism of sunitinib (6) in rat, monkey, and human. 
Metabolite M11 (82) was a major radioactive component in monkey urine and faeces. Glu – 
glucuronide; CYP – cytochrome P450 (van Erp et al., 2009, Speed et al., 2012).    
Scheme 8 – Metabolites of sorafenib (7). UGT – uridine glucuronosyl transferase; CYP – 
cytochrome P450 (Lathia et al., 2006, Ghassabian et al., 2012, Peer et al., 2012). 
Scheme 9 – Metabolic pathway of CAP (92). a) Carboxylesterase (liver); b) Cyd deaminase 
(liver, tumours); c) dThdPase (tumours) (Malet-Martino and Martino, 2002).  
Scheme 10 – Model proposed for AST-003 (97) bioactivation. a) Esterase (Huang et al., 
2015). 
Scheme 11 – Total syntheses of metabolite CGP74588 (52) and APG050 (58) (Kil et al., 
2007, Manley et al., 2013). Et3N – triethylamine.  
Scheme 12 – Total synthesis of metabolite M8 (74) (Caballero et al., 2012). PIFA – 
phenyliodine(III)bis(trifluoroacatate). 
Scheme 13 – Synthesis of metabolite M-2 (83) (Pleiss et al., 2006). DMF – 
dimethylformamide. 
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Table 1. Commonly used in vitro models of drug metabolism. 
In vitro model Advantages Disadvantages Requirements References 
Microsomes 
Vesicles of the 
endoplasmic 
reticulum; usually 
obtained from the 
liver and they 
contain CYP and 
UGT. 
Can be obtained 
from every organ or 
animal source; easy 
preparation and use; 
good long-term 
stability at -80 ºC; 
low cost; they can be 
obtained from frozen 
or portions of 
organs; fully 
characterized human 
microsomes are 
commercially 
available; inter-
individual variation 
can also be studied; 
one of the best 
characterized in vitro 
model for research in 
drug metabolism; it 
allows gathering 
information 
regarding metabolic 
profile, stability, 
metabolite 
identification, and 
kinetics. 
Non-microsomal metabolism is 
not studied, since other enzymes 
namely GST, NAT, and ST, and 
cytosolic cofactors are absent. 
Therefore, some metabolites are 
not detected that would have been 
formed in intact cells; 
unsuitability for quantitative 
estimations of in vivo human 
biotransformation because of the 
presence of high level CYPs and 
UGTs and no competition with 
other enzymes; the in vitro 
incubation conditions, such as the 
ionic strength, pH value of the 
incubation medium, and the 
organic solvents, can affect the 
outcomes of the studies. 
NADPH-
regenerating system, 
when CYP-mediated 
metabolism is 
studied. UDP-
glucuronic acid is 
required in the 
reaction media, when 
the glucuronidation-
mediated metabolism 
is to be studied. 
 
 
 
 
(Gunaratna, 
2000), (Asha 
and 
Vidyavathi, 
2010) 
Supersomes 
Microsomes and 
baculo virus (they 
are also called 
baculosomes) are 
placed in insect 
cells. 
Allow the unique 
specification of 
expressing enzyme 
activity of one single 
CYP isoform. 
In UGT supersomes, the UGT 
active site is shielded behind a 
hydrophobic barrier, resulting in 
latent glucuronidations, but this 
can be overcome using a pore-
forming agent like alamethicin; 
non-microsomal metabolism is 
not studied. 
Same requirements 
as microsomes. 
 
 
 
 
(Asha and 
Vidyavathi, 
2010), 
(Brandon et 
al., 2003) Cytosolic liver 
fractions 
Contain phase II 
enzymes such as 
GST, NAT, and 
ST; obtained by a 
differential 
centrifugation of 
whole-liver 
homogenate. 
Allow the 
biotransformation by 
NAT, ST, and GST 
to be studied either 
separately or in 
combination 
depending of the 
cofactors added. 
 
Only the soluble phase II 
enzymes present in the liver 
cytosol fractions can be 
investigated. The metabolic 
pathways of UGT or CYPs, 
which are located on the 
endoplasmic reticulum, cannot be 
investigated with this model. 
The factors to be 
added depend on the 
cytosolic enzyme to 
be studied. E.g. 
glutathione is 
required for GST 
catalysis. 
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 S9 fractions 
Correspond to the 
post-
mitochondrial 
supernatant 
fraction from 
homogenized 
liver. They are a 
mixture of 
microsomes and 
cytosol content of 
a tissue. 
Contain a wide 
variety of phase I 
and phase II 
enzymes including 
CYPs, flavin-
monooxygenases, 
carboxylesterases, 
epoxide hydrolases, 
UGT, ST, 
methyltransferases, 
acetyltransferases, 
GST and other drug 
metabolizing 
enzymes. 
As in microsomes, 
S9 fractions can be 
prepared from 
various tissues, 
although the most 
commonly used is 
the hepatic tissue. 
CYP activity in the S9 fractions is 
approximately 20–25% of those 
in the corresponding microsomal 
fraction. 
The factors to be 
added depend on the 
enzymes or group of 
enzymes to be 
studied. 
 
Cell lines 
Human liver cell 
lines include Hep 
G2 (from 
hepatocellular 
carcinoma), BC2 
(hepatoma), Hep 
3B 
(hepatocellular 
carcinoma), C3A 
(hepatoblastoma), 
PLC/PRF/5 
(hepatoma), 
HepaGR (from a 
human hepatic 
progenitor) and 
others. 
 
Can be isolated from 
primary tumours of 
the liver 
parenchyma; they 
are easy to culture 
and usually present a 
stable enzyme 
concentration. Cell 
lines are often used 
for drug metabolism 
studies when 
enzymes are induced 
and in cytotoxicity 
studies with the 
parental drug or its 
metabolites. 
Less popular for metabolic 
studies. Cell lines often go 
dedifferentiation of their cellular 
characteristics and they also have 
incomplete expression of all 
families of metabolic enzymes, 
when compared to other in vitro 
models. Since they have low 
expression or even null 
expression of some important 
phase I and phase II drug-
metabolizing enzymes, it is 
difficult to investigate the 
individual CYPs or other 
enzymes metabolites in this 
model. 
They should 
resemble the normal 
physiology of human 
hepatocytes in vivo 
and usually no 
addition of  
enzymatic cofactors 
is required. 
 
 
(Asha and 
Vidyavathi, 
2010), 
(Brandon et 
al., 2003) 
Transgenic cell 
lines 
A cell line 
expressing phase 
I and/or phase II 
enzymes through 
recombinant 
Are most useful for 
the characterization 
and identification of 
specific metabolic 
pathways, to 
generate metabolites 
for structure 
Higher price when compared to 
other in vitro models and this 
model does not reflect a complete 
in vivo situation as they express 
only the isozymes transfected. 
Usually no addition 
of  enzymatic 
cofactors is required. 
 
 
(Asha and 
Vidyavathi, 
2010), 
(Gasser et 
al., 1999) 
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expression of 
human enzymes 
in a cell line. 
elucidation and 
pharmacological 
characterization, to 
assess the potential 
drug-drug 
interactions at the 
metabolic level and 
to detect reactive 
products. They are 
easy to maintain in 
culture and allow the 
possibility of 
studying the 
enzymatic reactions 
of a single enzyme 
enabling even to 
detect residual 
metabolites.  
Isolated 
hepatocytes 
Primary cells are 
isolated from 
fresh liver tissue 
and can be used 
immediately after 
isolation or in 
culture for long-
term studies. 
Are used to study 
both phase I and 
phase II reactions 
since they contain 
both the enzymes 
and cofactors that a 
drug is likely to find 
in vivo in the liver. 
Moreover, 
cryopreserved 
hepatocytes are 
available 
commercially. 
Cultured or cryopreserved cells 
lose the CYP activity rapidly with 
increasing incubation time after 
seeding. Also, hepatocytes cannot 
be frozen and thawed or be 
prepared from previously frozen 
liver. As mentioned, cultured 
hepatocytes undergo gradually a 
loss of liver-specific functions 
with time, namely a decrease in 
CYP expression while 
cryopreserved hepatocytes retain 
the activity of most of phase I and 
phase II enzymes. There may be 
inter-individual variations 
between batches, which can be 
overcome by using mixtures of 
hepatocytes from multiple donors. 
Usually no addition 
of  enzymatic 
cofactors is required. 
 
 
 
(Gunaratna, 
2000), (Asha 
and 
Vidyavathi, 
2010), (Jia 
and Liu, 
2007) 
Tissue slices 
The incubation of 
liver slices in 
nutrient-rich 
media. 
Liver slices can be 
easily and rapidly 
produced. In 
addition, liver slices 
are not exposed to 
proteolytic enzymes, 
which can destroy 
important membrane 
receptors of the cell. 
They contain all the 
drug metabolizing 
Inadequate penetration of the 
perfusion medium can occur; 
liver slices cannot be 
cryopreserved and they have to be 
immediately used since they have 
a limited useful experimental 
period. 
Usually no addition 
of enzymatic 
cofactors is required. 
 
 
(Gunaratna, 
2000), (Asha 
and 
Vidyavathi, 
2010) 
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enzymes with all the 
cofactors present at 
relevant 
concentrations. 
Isolated perfused 
liver 
Perfused animal 
liver is useful in 
cases where bile 
secretion is 
important or 
when validation 
of other in vitro 
methods is 
required. 
Animal liver is used 
for 
biotransformation 
studies. This is 
regarded as correct 
model for human 
drug 
biotransformation. 
Poor reproducibility, labour-
intensive, and its functional 
integrity is limited to 3 h. 
The choice of the 
animal species 
requires some 
previous knowledge 
whether that animal 
species shares 
metabolic 
resemblance to 
human in that 
particular drug. 
 
 
(Asha and 
Vidyavathi, 
2010) 
CYP – cytochrome P450; GST – glutathione S-transferases; NADPH - nicotinamide adenine 
dinucleotide phosphate; NAT – N-acetyl transferases; ST – sulfotransferases; UGTs – glucuronosyl 
transferases. 
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Table 2. Synthesis of anticancer drug conventional metabolites.  
 
 
Method of synthesis 
 
Product 
 
Reference 
 
 
Chemical 
 
DOX (1) 
1. NaBH4 
2. O2 
 
 
DOXol (8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Takanashi and 
Bachur, 1976) 
 
 
 
 
 
Biological samples 
 
Was found in small 
amounts in some urine 
samples 
 
 
7-Hydroxydoxorubicin aglycone (9) 
 
Chemical 
 
DOX (1) 
1. H2   
Pd/BaSO4 
2. NaBH4 
3. O2 
 
 
 
7-Deoxydoxorubicinol aglycone (10) 
 
Chemical 
 
DOX (1) 
1. H2 
 Pd/BaSO4 
 
 
7-Deoxydoxorubicin aglycone (11) 
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 Enzymatic 
 
DOX (1) 
1. CH3COONa buffer 
pH 5.0 
2. Aryl 
sulfotransferase 
 
 
Demethyldeoxydoxorubicinol aglycone 
4-O-sulfate (12) 
 
 
 
 
 
 
 
 
 
 
 
 
(Takanashi and 
Bachur, 1976) 
 
 
 
 
 
 
Enzymatic 
 
DOX (1) 
1. CH3COONa buffer 
pH 4.5 
2. β-glucuronidase 
 
 
Demethyldeoxydoxorubicinol aglycone 4-O-β-
glucuronide (13) 
 
Chemical 
 
7-Hydroxydoxorubicin 
aglycone (9) 
1. NaBH4 
2. O2 
 
 
 
7-Hydroxydoxorubicinol aglycone (14) 
Chemical 
 
2,3-dihydro-1,4,5,8-tetra-
hydroxy-9,10-
anthracedione 
1. C4H12N2O and 
C7H16N2O2 
2. C6Cl4O2 
 
 
 
 
 
 
Monocarboxylic acid 16 of MTX 
 
 
 
 
(Chiccarelli et 
al., 1986) 
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 Chemical 
 
2,3-dihydro-1,4,5,8-tetra-
hydroxy-9,10-
anthracedione 
1. C7H16N2O2 
2. C6Cl4O2 
 
 
 
 
 
Dicarboxylic acid (17) of MTX 
 
 
 
 
 
(Chiccarelli et 
al., 1986) 
 
 
Enzymatic 
 
MTX (2) 
1. NH4CH3CO2 buffer 
pH 5/ H2O2 
2. Solid glutathione 
3. Horseradish 
peroxidase 
4. C6H8O6 
 
 
 
Glutathione conjugate (19) of MTX 
 
 
 
 
 
 
 
 
 
 
(Blanz et al., 
1991) 
 
 
Enzymatic 
 
MTX (2) 
1. NH4CH3CO2 buffer 
pH 5/ H2O2 
2. Horseradish 
peroxidase 
3. C6H8O6 
 
 
 
 
Cyclic naphthoquinoxaline (20) of MTX 
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Chemical  
 
4-Hydroperoxycyclophos-
phamide (37) 
1. Cacodylate buffer  
2. Na2S2O3 
3. HCl 
 
 
 
 
4-Hydroxycyclophosphamide (28) 
 
 
 
 
 
 
 
 
 
(Manthey and 
Sladek, 1988) 
 
 
 
Aldophosphamide (29) 
 
 
Chemical 
 
 Phenylphosphorodichlori-
date 
1. Mono- or bis-(2-
haloethyl)amine 
2. NH3 or 2-
haloethylamine 
 
 
 
 
 
 
Phosphamide mustard (30) 
 
 
 
 
(Struck et al., 
1994) 
 
 
Chemical  
 
Formaldehyde 
1. CH3CHO 
 
 
 
 
 
 
Acrolein (31) 
 
 
 
 
(Dumitriu et 
al., 1993) 
  JU
ST
 AC
CE
PT
ED
 Chemical 
 
Bis(2-chloroethyl)amine 
1. POCl2 
2.  
3. Et2N 
4. NaH 
 
 
 
 
4-Ketocyclophosphamide (32) 
 
 
 
 
(Hill et al., 
1970) 
 
Enzymatic 
 
CTX (3) 
Oxidation by aldehyde 
dehydrogenase (ALDH) 
 
 
 
Carboxyphosphamide (33) 
 
 
 
 
 
(Ludeman, 
1999) 
 
Chemical 
 
2-chloroacetic acid 
1. NaBH4 
2. DNPH 
 
 
 
 
Chloroacetaldeyde (38) 
 
 
 
(Shaw et al., 
1983) 
 
 
Chemical  
 
5-FdUrd (51) 
1. MMTrCl, pyridine 
2. Ac2O, pyridine 
3. 80% AcOH 
4. NCCH2CH2OPO3H2, 
DCC, pyrimidine 
5. LiOH, CH3OH, 
H2O 
 
 
5-FdUMP (39) 
 
 
 
 
 
(Abraham et 
al., 1996) 
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 ALDH - aldehyde dehydrogenase; Ac2O – acetic anhydride; AcOH – acetic acid; BaSO4 - barium 
sulfate; C6H8O6 - ascorbic acid; CH3CHO - acetaldehyde; C6Cl4O2 – chloranil; C4H12N2O - 2-(2-
Aminoethyl-amino)ethanol;   C7H16N2O2 - tert-butyl-2-aminoethyl-aminoacetate; CH3COONa - 
Sodium acetate; CH3OH  - methanol; (CH3O)3PO – trimethyl phosphate; CH3CN – acetonitrile; DCC 
– N,N'-dicyclohexylcarbodiimide; DNPH – 2,4-dinitrophenylhydrazine; Et2N – diethylamine; H2 – 
hydrogen; NH3 – ammonia; HCl - hydrochloric acid; LiOH - lithium hydroxide; MMTrCl – 4-
methoxytriphenylchloromethane; NaBH4 - sodium borohydride; NaH - sodium hydride; Na2S2O3 - 
sodium thiosulfate; NH4CH3CO2 - ammonium acetate; (NH4)2Ce(NO3)6 - ammonium cerium (IV) 
nitrate; O2 – oxygen; Pd – palladium: POCl2 - phenylphosphonic dichloride; POCl3 - phosphoryl 
chloride. 
 
 
Chemical  
 
5-FUrd (50)  
1. POCl3 
2. (CH3O)3PO 
 
 
 
5-FUMP (42) 
 
 
 
(Fujita et al., 
1994) 
 
 
 
Chemical  
 
1,3-bis-(4-
methoxybenzyl)-5,6-
dihydro-5-fluorouracil  
1.  CH3CN 
2.  (NH4)2Ce(NO3)6 
3. H2O 
 
 
 
 
 
5-FUH2 (46) 
 
 
 
(LaFrate and 
Katzenellenbogen, 
2007) 
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